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Background: Obstructive airway diseases (OADs) are among the leading causes of morbidity 
and mortality worldwide. Shortness of breath (SOB) is the main symptom associated with 
OADs. International guidelines from the Global Initiative for Chronic Lung Disease (GOLD) 
and the Global Initiative for Asthma (GINA) have recommended spirometry as an indispensable 
tool for the diagnosis of asthma and chronic obstructive pulmonary diseases (COPD), but 
spirometry is rarely used in family practice. Simple and reliable diagnostic tools are necessary 
for screening community patients with onset of OADs for timely management. 
Purpose: This thesis examined screening utility of the PiKo-6 forced expiratory volume in one 
second (pFEV1) , in six second (pFEV6), and the pRatio ( pFEV1/pFEV6) in SOB patients for 
OADs in community  pharmacy settings. FEV6 has recently been suggested an excellent 
surrogate for Forced Vital Capacity (FVC), which requires maximum exhalation of the lungs.   
Methods: Patients with SOB symptoms who were prescribed pulmonary inhalers, by their 
family physicians, were recruited via community pharmacies. Trained pharmacists collected two 
PiKo-6 tests to assess the repeatability of the PiKo-6 device. All patients performed laboratory 
spirometry ( FEV1, FVC and FEV1/FVC)  to obtain physician diagnosis of their OADs. The 
results of the PiKo-6 spirometer and laboratory spirometer were compared. In addition, the 
PiKo-6 pRatio and laboratory FEV1/FVC were assessed against physician diagnosed COPD.   
Results: Sixty three patients volunteered to perform the PiKo-6 spirometry. Of these, 52.4 % 
were men (age 53.9 ± 15.3 years; BMI 31.9 ± 7.40 kg/m2). Repeated testing with pFEV1, pFEV6 
and pRatio correlated signiﬁcantly (within correlation, r = 0.835, p-Value≤ 0.05 ; 0.872, p-
Value≤ 0.05; and 0.664, p-Value≤ 0.05). In addition, pFEV1, pFEV6 and pRatio correlated 
signiﬁcantly with FEV1, FVC and FEV1/FVC, respectively (between correlation = 0.630, p-
Value≤ 0.05 ; 0.660, p-Value≤ 0.05  and 0.580, p-Value≤ 0.05). The cut-off value corresponding 
to the greatest sum of sensitivity and specificity of pRatio for physician-diagnosed COPD was 
<0.80, the sensitivity and specificity were 84 % and 50%, respectively.  
Conclusions The portable PiKo-6 correlates moderately well with the standard spirometry, when 
delivered by community pharmacists to patients with OADs. The PiKo-6 spirometer may play a 
role in screening patients suspected of having an OAD in community pharmacies that may 
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Chapter 1: Introduction 
1.1 Background and study rationale 
Obstructive airway diseases (OADs) are among the leading causes of morbidity and 
mortality worldwide, and its prevalence has increased globally in the last few decades. 
International guidelines on lung diseases from the Global Initiative for Chronic Lung Disease 
([GOLD], 2014) and the Global Initiative for Asthma ([GINA], 2014) have recommended the 
use of spirometry in pulmonary function testing (PFT) as an indispensable tool for the diagnosis 
of OADs. Asthma and chronic obstructive pulmonary disease (COPD) are two of the most 
common OADs that require spirometry for diagnosis. However, spirometers are widely 
inaccessible in family practice. Community patients with shortness of breath (SOB), the main 
symptom associated with OADs, may have been provided an unreliable diagnosis due to the 
underutilization of spirometry which is required to evaluate and diagnose the underlying disease 
(Walters et al., 2011). Portable spirometers might play a crucial role in screening community 
patients for adequate and timely management of OADs. The main objective of this thesis is to 
evaluate whether the portable PiKo-6 spirometer, obtained in community pharmacy settings, 
correlate well with the standard laboratory PFT. 
1.2 Overview 
1.2.1 Dyspnea and shortness of breath 
Dyspnea refers to the sensation of difficulty in catching one’s breath, simply termed 
shortness of breath (SOB). The American Thoracic Society (ATS) defines SOB as "a subjective 
experience of breathing discomfort that consists of qualitatively distinct sensations that vary in 
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intensity” (Meek et al., 1999). The ATS definition suggests that SOB is a complex and 
multidimensional concept that is subjective and may not be inferred from clinical or laboratory 
investigations (Parshall et al., 2012). SOB is an expected outcome of excessive physical activity; 
nevertheless, it is considered pathologic if it occurs during rest (Shiber & Santana, 2006). Often, 
patients with SOB may experience suffocation, chest tightness or difficulty in catching their 
breath. In most cardiopulmonary diseases, SOB is caused by both increased ventilatory demand 
and altered ventilatory mechanics (Parshall et al., 2012). The severity of SOB is correlated with 
advanced age, some occupational settings, cigarette smoking, and the presence of major 
cardiopulmonary diseases (Wahls, 2012; Parshall et al., 2012; Currow et al., 2009). SOB afflicts 
many Canadians and it remains difficult to diagnose, treat, or manage in family practice settings.  
1.2.2 Epidemiology of SOB associate diseases 
The prevalence of cardiopulmonary disease in Canada is rising. The public Health 
Agency of Canada (PHAC) estimates that 3 million Canadians are suffering from respiratory 
diseases (PHAC, 2007). Lung diseases have a major impact on the individual, the family, the 
community, and the health care system. After cardiovascular disease and cancer, chronic 
respiratory diseases (CRD) account for most hospitalizations and deaths (PHAC, 2007). 
 SOB is the single most common symptom underlying many restrictive and obstructive 
lung and heart diseases. Asthma, chronic obstructive pulmonary disease (COPD), pulmonary 
hypertension, and heart failure are known diseases which cause SOB. Table 1 presents the 
differential diagnosis for SOB associated diseases in community patients who presented to 
primary care practice in Amsterdam, Netherlands (Ponka & Kirlew, 2007). The authors assumed 




Table 1.1 Percentages of the differential diagnosis of shortness of breath by age groups (under 
45 years compared to over 45 years) 
Differential Diagnosis Age Groups 
Under 45 years  45 years and older 
Asthma 31.80 % 9.90 % 
Acute Bronchitis 21.50 14.70 
COPD 1.50 23.70 
Congestive Heart Failure 0.07 15.30 
Dyspnea Not-Yet-Diagnosed 7.00 8.20 
Anxiety 7.80 3.30 
Upper Respiratory Infection 6.70 1.50 
Pneumonia 2.50 3.30 
Acute Laryngitis/Tracheitis 4.70 1.00 
Ischemic Heart Disease 0.20 2.30 
Lung Malignancy 0.00 1.30 
Pulmonary Embolism 0.30 0.50 
Other 16.00 15.00 




Asthma is an inflammatory airway disease with onset rooted in a complex set of 
environmental, genetic, socioeconomic, and medical factors (Ober & Yao, 2011). The Global 
Initiative for Asthma (GINA) defined asthma as: 
“a heterogeneous disease, usually characterized by chronic airway inflammation. It is 
defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest 
tightness and cough that vary over time and intensity, together with variable expiratory 
airflow limitation.” (GINA, 2014). 
Asthma causes an obstruction of the small airways (bronchioles) and bronchial tubes of the 
lungs. The disease varies in severity and frequency among individuals. During an asthma attack, 
the lining of the bronchial tubes swells causing the airways to narrow, reducing normal airflow in 
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and out of the lungs (World Health Organization [WHO], 2014). The pathogenesis of asthma is 
unknown, and there are no laboratory blood tests or biomarkers that definitively diagnose asthma 
or distinguish it from other diseases (Ober & Yao, 2011). When symptoms are not adequately 
controlled, it can limit the physical, emotional, and social lives of asthmatics.  
Diagnosis 
Clinical diagnosis of asthma is primarily based on identifying recurrent appearances of 
symptoms such as wheezing, SOB, chest tightness or cough, and variable expiratory airflow 
limitation (GINA, 2014). When in doubt, asthma is diagnosed with examination of spirometry 
results. Reversibility of symptoms, that improve or disappear after bronchodilator medications, is 
required to definitively diagnose asthma (GINA, 2014). Baseline assessment of pulmonary status 
can include pulse oximetry, chest radiograph, electrolyte levels, and arterial blood gas (ABG) 
analysis. ABG analysis may be used to test for cardiac diseases associated with SOB. 
Treatment and Management 
Four surveys regarding asthma in America, Europe, Asia-Pacific, and Japan highlighted 
that asthma is underdiagnosed and undertreated, with significant opportunity for improvements 
in asthma control (Braman, 2006). To et al. (2012) indicated that asthma control is not ideal in 
many countries and estimated that nearly half of the asthma population in the world reported 
wheezing in the last 12 months, but only a moderate proportion had been diagnosed and/or 
received treatment. Asthma management aims to decrease exacerbations, airflow obstruction, 
and side effects of treatment (GINA, 2014). The patient – healthcare provider partnership is 
crucial to achieve effective asthma management. This partnership could empower patients to 
take a major role in managing their asthma (GINA, 2014). Asthma can be treated and managed 
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by primarily using pharmacological methods; in addition, non-pharmacological methods could 
be beneficial in managing asthma.  
Currently, there is no cure for asthma, but appropriate assessment and management using 
pharmacologic treatments to control asthma may prevent frequent exacerbation and enhance a 
patient’s quality of life. GINA recommends that every patient with asthma should have a reliever 
medication, and most adults and adolescents with asthma should have a controller medication 
(GINA, 2014). Spirometry examinations are usually repeated to assess the efficacy of the 
medication. In addition to medications, non-pharmacological strategies and interventions may be 
considered to manage asthma symptoms and exacerbations. These strategies include: promoting 
smoking cessation, improving physical activity, and removing occupational sensitizers (GINA, 
2014). There are many types of triggers or allergens such as tobacco smoke, stress, and physical 
exercise. To avoid frequent asthma exacerbations, it is recommended that patients recognize and 
avoid what triggers their asthma (WHO, 2013).  
Written Acton Plans (WAP) are a set of tailored instructions designed to help a person 
with asthma to understand their worsening symptoms and the response required. GINA 
recommends that asthmatic patients should be provided with a WAP, appropriate for their level 
of asthma control and health literacy, which include: the patient’s usual asthma medications, 
when and how to increase medications, and how to access medical care if symptoms fail to 
respond (GINA, 2014). Unfortunately, evidence suggests that as few as 25% of eligible patients 
receive WAPs from their physician or other health care professionals (Rank et al., 2008). 
Prevalence and Incidence Rates 
Worldwide: According to the World Health Organization (WHO), about 235 million 
people currently suffer from asthma; in addition, it is the most common non-communicable 




In 2013, Statistics Canada reported the percentage of population aged 12 and over, who 
reported that they have been diagnosed by a health professional as having asthma. The 
percentage with asthma was 8.8% in Alberta, 7.3% in Saskatchewan, and 8.2% in Newfoundland 
(Statistics Canada, Canadian Community Health Survey[CCHS],  2013). Between 2001 and 
2013, females (8.9% ) were more likely than males (6.9%) to report that they had asthma. Figure 
1.1 shows that asthma prevalence changes as the population ages. The high prevalence in young 
boys is not maintained into adulthood. The highest prevalence in females is during adolescence 
and it remains higher than males into adulthood (Statistics Canada, 2013). 
Epidemiological Challenges 
In epidemiological studies, measuring prevalence and incidence of asthma presents a 
challenge due to the evolving definition and the inconsistent use of clinically objective 
measurements for diagnosis. It is difficult to compare the results from different studies due to the 
differences in the definitions currently available (To et al., 2012; Jia et al., 2013). Furthermore, 
the symptoms of asthma are nonspecific and have multiple differential diagnoses. Another 
reason for the epidemiology challenges when studying asthma is the lack of a gold-standard 
diagnostic test (Sears, 2014). Increased exposure to indoor allergens and poor air quality are 
some of the factors that increased asthma prevalence (American College of Preventative 
Medicine [ACPM], 2013). Although urbanization is correlated with an increased risk of asthma 
incidence, the nature of the risk is unclear (Robinson et al., 2011).   
Economic burden 
Morbidity from asthma can be defined in several ways: asthma exacerbations, physician 
visits, emergency department (ED) visits, and hospitalizations. ED visits and hospitalization due 
to asthma causes a significant economic burden on the health care system. The WHO (2014) 
stated that the global cost of asthma is estimated to surpass the combined cost of tuberculosis and 
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acquired immune deficiency syndrome. Among patients presenting to the ED for acute asthma 
treatment in Canada, 51% reported having an unscheduled visit in the previous year and 30% 
reported having one or more ED visits per year (Rowe et al., 2010). The Conference Board of 
Canada stated that the combined direct and indirect costs of asthma would increase from $2.2 
billion in 2010 to about 4.2 billion by 2030 (Thériault, et al., 2012).  
Mortality 
Approximately 250,000 people die prematurely each year from asthma, and most of these 
deaths are avoidable (WHO, 2007). In Canada, asthma mortality in one year averages 
approximately 250 people (Conference Board of Canada, 2012).  Despite advances in 
understanding of the disease, several factors have been linked to asthma deaths. Omachi et al. 
stated that greater severity-of-asthma scores and poorer perceived asthma control scores were 
each associated with increased mortality risk among adults with severe asthma (Omachi et al., 
2008).  
1.2.2.2 Chronic Obstructive Pulmonary Disease 
Etiology 
It refers to a group of lung diseases that include chronic bronchitis and/or emphysema. 
COPD is directly related to the prevalence of smoking (Global initiative for chronic Obstructive 
Lung Disease [GOLD], 2014). GOLD defined COPD as: 
“ a common preventable and treatable disease, is characterized by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to the overall 
severity in individual patients” (GOLD, 2014).   
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This indicates that the etiology of COPD involves a complex set of genetic determinants, lung 
injury due to excessive smoking, and environmental stimuli (Decramer, Janssens, & Miravitlles, 
2012). Elbehairy et al., stated that COPD is associated with extensive impairment of small 
airway function, progressive morbidity and reduced life-expectancy (Elbehairy, Webb,  Neder, & 
O’Donnell, 2013). 
Diagnosis 
The Global initiative for chronic Obstructive Lung Disease (GOLD) stated that a clinical 
diagnosis of COPD should be considered in any patient who has SOB, chronic cough or sputum 
production, family history of COPD and a history of exposure to risk factors of the disease, such 
as: tobacco smoke, smoke from home cooking and heating fuels, and occupational dusts and 
chemicals (GOLD, 2014). Spirometry is the primary diagnostic tool for COPD. Forced 
Expiratory Volume in one second (FEV1) is the volume exhaled during the first second of a 
forced expiratory maneuver started from the level of total lung capacity. Forced Vital Capacity 
(FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest 
breath possible. The presence of a post- bronchodilator FEV1/ FVC < 0.70 confirms the presence 
of persistent airflow limitation (GOLD, 2014). Elbehairy et al., recommend screening by 
spirometry in smokers at risk (Elbehairy, Webb, Neder, & O’Donnell, 2013). Other strategies 
may be considered as part of the diagnosis and assessment of  COPD which includes: chest 
radiographs, lung volumes and diffusing capacity, oximetry and ABG analysis, alpha-1 
antitrypsin deficiency screening, exercise testing, and composite scores (GOLD,  2014).   
There are four integral components for COPD assessment: symptoms, degree of air flow 
limitation, risk of exacerbations, and comorbidities (GOLD, 2014). GOLD created a rubric for 
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combining these assessments to improve COPD management (GOLD, 2014). The degree of 
airflow limitation is classified based on post- bronchodilator FEV1. Patients with COPD are 
classified into four grades: GOLD 1 has a mild airflow obstruction with FEV₁ ≥ 80% of 
predicted; GOLD 2 has a moderate airflow obstruction with FEV₁ 50–80% of predicted; GOLD 
3 has a severe airflow obstruction with FEV₁ 30–50% of predicted; and GOLD 4 has a very 
severe airflow obstruction with FEV₁ < 30% of predicted. This definition provides an objective 
method to classify the severity of airflow limitation in COPD (GOLD, 2014). 
Treatment and Management 
Unfortunately, about 60-85% of COPD patients, especially in its mild to moderate stages, 
remain undiagnosed (Decramer et al., 2012). Both pharmacological and non-pharmacological 
management strategies are crucial in the management of COPD exacerbations. Pharmacologic 
therapy is used to reduce symptoms, reduce the frequency and severity of exacerbations, and 
improve health status and exercise tolerance (GOLD, 2014). Non-pharmacological strategies 
improve health status and quality of life, reduce healthcare utilization, and costs by preventing 
the frequency and severity of COPD exacerbations (Suh, Mandal, & Hart, 2013).  
Smoking cessation is the most important factor that influences the natural history of 
COPD (GOLD, 2014). Non-pharmacological management strategies include the following: 
pulmonary rehabilitation, non-invasive ventilation, smoking cessation, long-term oxygen 
therapy, tele-health programs, and physiological monitoring (Suh, Mandal, & Hart, 2013). 
Furthermore, physical activity is beneficial for COPD patients; and they should repeatedly be 





Prevalence and Incidence Rates 
Worldwide:  The prevalence and mortality rates of COPD are increasing worldwide; and 
therefore remains a relevant public health problem. In 2008, the WHO predicted COPD to be the 
third leading cause of death by 2030 globally. COPD affected approximately 329 million people 
(4.8% of the global population) in 2010, which is much higher than the earlier figure of 64 
million in 2004 (Vos et al., 2012). 
Canada: Although COPD is a preventable and treatable condition; it is the fourth leading 
cause of death in Canada (Statistics Canada, 2011). In 2009, approximately 4.2% of the 
population (aged 35 and over) reported that they had been diagnosed with COPD. This rate did 
not change significantly from 4.6% in 2008, and there was no significant difference between the 
sexes (Statistics Canada, 2011). Direct measurements of lung function from the Canadian Health 
Measures Survey ([CHMS], 2013) indicated that 13% of Canadians had a lung function score 
indicative of COPD, which is three times higher than the reported rate (Statistics Canada, 2013). 
This disparity between reported and measured COPD in the CHMS suggests under diagnosis of 
the disease in Canada (Evans et al., 2014). 
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Figure 1.2: Prevalence of physician-diagnosed COPD by age and sex in Canada, 2009 
 
In 2013, the Alberta, Saskatchewan, and Newfoundland population aged 35 and over, 
who reported being diagnosed by a health professional with chronic bronchitis, emphysema or 
COPD was reported at 4.1%, 3.2%, and 4.9% respectively (Statistics Canada, CCHS, 2013). 
Figure 1.2 shows how COPD prevalence changes as the population ages. Among men, COPD 
rates increased steadily from age 35 and remained high; on the other hand, women’s COPD rates 
increased from age 35 but leveled off at age 65 (Statistics Canada, 2011).  
Epidemiological challenges 
Estimates of the prevalence and incidence of COPD are very dependent upon the 
definition of COPD. This limits the comparability of the prevalence and incidence between 
studies. There are various risk factors that led to the increased prevalence of COPD. Its primary 
cause is tobacco smoke, including second-hand or passive exposure. Another risk factor is 
13 
 
exposure to air pollution, such as in the use of biomass fuels. Occupational exposure to dusts 
causes SOB, thus avoiding dust may reduce COPD exacerbations (Rehm et al., 2007). Also, 
genetic causes may also play a role in increasing the risk of COPD. This includes the deficiency 
of alpha-1-antitrypsin, an anti-protease which protects the lung tissue from damage, and 
predisposes patients to COPD (Rehm et al., 2007).  
Economic burden 
An acute exacerbation of COPD has detrimental effects on lung function, health-related 
quality of life (HRQL), and exercise capacity (Suh, Mandal, & Hart, 2013). COPD imposes a 
significant economic burden on healthcare systems. The Conference Board of Canada stated that 
the combined direct and indirect costs of COPD would increase from just under $4 billion in 
2010 to about 9.5 billion by 2030, an increase of 140 per cent (Thériault, et al., 2012). In 2010, 
the three major chronic lung diseases, costing Canada’s economy $12 billion, were asthma, 
COPD, and lung cancer; with the annual economic burden predicted to double by 2030 if 
strategies to manage respiratory disease are not developed (the Conference Board of Canada, 
2012).  
In 2011, Statistic Canada conducted a “Survey on Living with Chronic Diseases in 
Canada (SLCDC)”. The survey included a nationally representative sample of 1,133 Canadians 
aged 35 years and older who reported being diagnosed with COPD by a health professional. 
They stated that COPD is devastating in nature and negatively impacts an individual’s quality of 
life. Among Canadians with COPD, 45% reported their overall health as "fair or poor” (PHAC, 
2012). COPD affected their activities of daily living and occupational status by reducing the 
number of hours worked or changing the type of work. As COPD progresses, it limits the quality 
of life and activity levels due to SOB (Rehm et al., 2007). According to the Canadian Institute 
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for Health Information [(CIHI), 2008], COPD now accounts for the highest rate of hospital 
admission among major chronic illnesses in Canada. In addition, it has a much higher 
readmission rate than other chronic illnesses.  
Respiratory diseases pose a significant economic burden on the Canadian health care 
system due to both direct and indirect costs. Currently, almost 6.5% of total health care costs 
were related to respiratory diseases (not including lung cancer) (PHAC, 2007). The direct costs 
result from outpatient and inpatient care expenses; alternatively, the indirect costs arise due to 
the loss of productivity. Mittman et al., estimated the total cost of COPD hospitalization in 
Canada to be $1.5 billion a year (Mittman et al., 2008).  
Mortality 
COPD is preventable as the majority of cases are caused by smoking. Smoking is 
accountable for approximately 80% of deaths from COPD (Rehm et al., 2007). Quitting smoking 
has been associated with improved lung function, reduced chronic cough and airway mucus 
production, and decreased mortality from COPD (PHAC, 2012). In China, with one-third of the 
world’s smokers, the current predictions of the annual COPD mortality rate will be over 2 
million by 2033 (Lin, Murray, Cohen, Colijn, & Ezzati, 2008).  
1.2.2.3 Cardiopulmonary diseases associated with Shortness of Breath 
In addition to obstructive diseases, SOB can be an underlying symptom for restrictive 
lung diseases. Restrictive diseases affect the volume of the lungs more than actual airway flow. 
The expansion of the lung is restricted which reduces lung capacity, either due to loss of alveolar 
volume, or diseases of the chest wall, pleura or neuromuscular impairment. Thus, the lungs of 




Heart Failure (HF) is a physiological state that occurs when the heart cannot pump 
enough blood to meet the metabolic needs of the body. There are many risk factors that increase 
incidence of HF with poor predicted outcomes such as ischemic heart disease, hypertension, 
smoking, obesity, and diabetes (Bui, Horwich, & Fonarow, 2010). HF is a major public health 
issue and it afflicts 23 million people across the globe (Lloyd-Jones et al., 2010; McMurray, 
Petrie, Murdoch, & Davie, 1998). More than 550,000 individuals are diagnosed with HF every 
year in Canada; in addition, there is a lifetime risk of one in five to develop this syndrome 
(Lloyd-Jones et al., 2010; Levy et al., 2002). Depending on the severity of symptoms, heart 
dysfunction, age, and other factors, HF can be linked with an annual mortality rate between 5% 
and 50% (Arnold et al., Canadian Cardiovascular Society [CCS], 2006). 
Pulmonary arterial hypertension (PAH) is a rare chronic disease that affects both the 
heart and lungs. It occurs due to proliferation of smooth  muscles and vascular endothelium of 
pulmonary arteries. It leads to impaired diffusion and decreased supply of the oxygenated blood. 
As a result, patients with PAH suffer from SOB, fatigue, and eventually it leads to right HF 
(National Heart, Lung, and Blood Institute [NHLBI], 2014). As a result, patients with PAH 
suffer from SOB, fatigue, and eventually it leads to right HF (NHLBI, 2014). Peacock and 
colleagues suggested that previous reports, from specialist centres of pulmonary arterial 
hypertension management, underestimated the true incidence and prevalence of PAH; 
furthermore, they stated that no studies have examined the epidemiology of PAH beyond the 
experiences and records of specialist centres and national registries (Peacock et al., 2007).  
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1.3 Care gaps exist in diagnosis, treatment and management of SOB patients 
Many diseases have SOB as a common symptom that causes a wide spectrum of 
challenges for family physicians (FPs). Therefore care gaps may exist in terms of diagnosis, 
treatment, management, and prognosis for the specific disease underlying this condition. 
Community patients with onset of asthma and COPD are often poorly managed. Spirometry, the 
primary component of pulmonary function tests (PFTs), and full PFTs are required to diagnose 
the two most common types of obstructive airways diseases - asthma (reversible) and COPD 
(non-reversible). These evaluations however, are not often performed. 
Most patients with SOB are prescribed pharmacological therapy without a full diagnostic 
workup for the cause of the symptoms. Therefore innovative research programs that are designed 
to assess patients’ outcomes and management are needed to elucidate where the care gaps exist. 
1.4 Community pharmacy assisted interventions 
Recently, changes in the scope of practice across Canada enhanced the participation of 
pharmacists with other healthcare professionals to provide primary healthcare and chronic 
disease management. Pharmacists are accessible and are often the first point of entry into the 
health care system (Tsuyuki et al., 2002). They are present in almost every community, and see 
patients more frequently than physicians. Dr. Ross Tsuyuki’s research group in Edmonton has 
pioneered the development of networks of community pharmacists as a public health approach to 
chronic disease management. As an example, his study of Cardiovascular Risk Intervention by 
Pharmacists (SCRIP) recruited 675 patients in 54 centres; the study was a randomized trial of a 
community pharmacist intervention versus usual care in patients at high risk for cardiovascular 
events (Tsuyuki et al. 2002). Patients were identified by the community pharmacists through 
medication indicators, such as use of nitroglycerin or oral hypoglycemic agents. In the SCRIP 
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study, patients received a multifaceted intervention aimed at improving cholesterol risk 
management. Dr. Tsuyuki’s research group successfully extended a pharmacy management 
model to include improving care in asthma, osteoporosis, osteoarthritis, hypertension, and 
diabetes. 
In this thesis, we are interested in assessing how a community pharmacy may help in the 
screening patients suspected to have OADs by using the PiKo-6 portable spirometer. At the time 
of the study initiation, there was no study conducted to assess the use of the PiKo-6 in 
community pharmacies to screen patients for OADs. The PiKo-6 could be the first diagnostic 
















Chapter 2: Pulmonary Function Testing  
2.1 Spirometry - the primary diagnostic tool for airway disease 
Pulmonary function testing (PFT) is the main diagnostic tool for quantifying respiratory 
effort and detecting airway obstruction. Spirometry, the measurement of airflow, is the most 
useful component of PFT to detect airway obstruction. Spirometry is the most reproducible and 
objective measurement of airflow limitation available (GOLD, 2014). Qaseem et al., 
recommends spirometry for patients with SOB (Qaseem et al., 2011). Spirometry measures lung 
function by quantifying the amount (volume) and /or speed (flow) of air that can be inhaled and 
exhaled in forced breathing. In a laboratory, PFT is performed using a device called a spirometer, 
which comes in several different varieties such as the HDpft 3000™, SpiroAir ™ and Body 
Plethysmograph ™. Most spirometers display the rate of airflow and the total volume of air 
inspired or expired in graphs called spirograms. PFT varies slightly depending on the settings, 
the equipment used, and the patient’s current effort at discharging air out of the lungs (Mason et 
al., 2010).  
Generally, patients performing spirometry are asked to take the deepest breath possible, 
and then exhale into the sensor as hard as possible for the longest possible time at best effort to 
discharge the total volume of air in the lungs. This procedure may be directly followed by a rapid 
inhalation (inspiration), especially when evaluating possible upper airway obstruction. During 
the test, a soft nose clip is used to prevent air from escaping through the nose. Filtered 
mouthpieces are also used to prevent the spread of microorganisms. In family practice, the 
volume of air discharged during breathing and flow rates that are of interest to patient care are 
recoded as: Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), Peak 
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Expiratory Flow (PEF), Ratio of FEV1/FVC, and Forced Expiratory Time (FET) (Coates et al., 
2013).  
Smokers, especially those likely to develop COPD, experience an increased rate of 
decline in FEV1 (Vestbo et al., 2011). FVC is the total volume of exhaled air from the deepest 
inspiration to total exhalation. The FEV1/FVC ratio, which represents the % of air that can be 
expelled in the first second, defines COPD and also provides insight to its severity. Experienced 
pulmonologists will use flow-volume loops, with the graphical display of the relationships 
between the flow rates and volumes during a forced exhalation, to diagnose patients with the  
presence of airway obstruction. Family physicians (FP) or clinicians, who are less familiar with 
PFT diagnosis, may find that numerical data of FEV1 and the FEV1/FVC ratio are more useful. 
PEF, the maximum flow rate achieved during the forced exhalation, can be obtained using an 
inexpensive portable handheld peak flow meter for domestic use. Although the PEF is not a 
diagnostic tool, it can be used for practical monitoring to help patients and clinicians monitor the 
course of asthma and to detect early increase in airway obstruction (GINA, 2014). FEV1 from 
spirometry is more reliable than PEF; as a result, it is recommended to replace PEF with FEV1 
(GINA, 2014). 
In PFT, the addition of beta-agonist inhalation to standard spirometry allows assessment 
of reversible airway obstruction.  First, a baseline spirometry is performed followed by 
administration of an inhaled bronchodilator, either by meter-dose inhaler or by a nebulizer. After 
15 minutes, the spirometry is repeated. An improvement in FEV1 of 12-15 % from the baseline is 
considered a positive response, which supports a diagnosis of reversible airway obstructive 
disease (GINA, 2014). In the absence of an acute viral infection, a 12-15 % improvement from 
the baseline in FEV1 is also sufficient evidence for a diagnosis of asthma.  
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Patients with suspected airway obstruction may not show airflow limitations at the time 
of initial assessment. As a result, they may be referred to perform a bronchial provocation test to 
assess airway hyperresponsiveness (GINA, 2014). The bronchial provocation test uses a variety 
of potentially broncho-provocative stimuli, including allergens, methacholine, histamine, 
exercise, and/ or cold air. This bronchial provocation test applies to patients suspected with 
asthma rather than COPD. It allows for diagnosis of reversible airway obstruction, especially in 
more borderline or asymptomatic patients who are suspected to have asthma but have no history 
of SOB symptoms, coughing or wheezing.   
The American Thoracic Society (ATS) developed standard guidelines for the 
performance and interpretation of PFT. These guidelines are reviewed, revised, and updated each 
year. When interpreting spirometry results, it is essential to evaluate airway obstruction, 
acknowledge the patients’ baseline history, physical evaluation, and clinical symptoms. Figure 
2.1 presents the diagnostic algorithm for obstructive airway diseases in patients with SOB. 
   
Figure 2.1 Diagnostic algorithm for shortness of breath (modified from Hueston, 2002). 
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 In spirometry testing, a ratio of FEV1/FVC that is lower than 70% is a diagnosis of 
airway obstruction (GOLD, 2014). If the obstruction is reversible with inhalation of a beta- 
agonist, asthma is the most likely diagnosis. Patients with COPD may have reversibility, but it is 
usually minor. If the reversibility element is large in a patient with obvious COPD, 
distinguishing asthma from COPD can be problematic, particularly in smokers and older adults. 
The consensus-based description of patients with Asthma and COPD Overlap Syndrome 
(ACOS) is currently available in the GINA and GOLD reports (GINA, 2014; GOLD, 2014). 
Alternatively, a low FVC accompanied with normal FEV1/FVC suggests a restrictive defect. 
These patients may be carefully evaluated using other diagnostic modalities to determine the 
underlying cause of the disease, which may include a variety of diseases. 
Several patient and laboratory factors, other than the underlying disease, may affect PFT 
or spirometry variability in determining airway obstruction. Factors such as age, gender, height, 
and ethnicity are considered in calibration of the spirometer test results. Many laboratory 
spirometers calculate both the actual test value and the predicted value. The predicted value 
adjusts for age, gender, height, and ethnicity when reporting a patient’s performance against the 
normal values.  
2.2 The need for portable spirometry in family care practice 
Although adult patients with SOB symptoms require spirometry to obtain a diagnosis for 
their airway diseases, only a few FPs perform these tests to provide optimal care for their 
patients. In a study that reviewed 3072 patients in an asthma research group in Alberta, only 25% 
of patients in family practices had PFTs performed (Tsuyuki et al., 2005). In addition, Gershon et 
al., stated that only about one third of individuals who had been given a diagnosis of COPD in 
Ontario, Canada, received PFT to confirm their diagnosis of COPD (Gershon et al., 2014). Aaron 
23 
 
et al., found that one-third of Canadians with physician-diagnosed asthma did not have asthma 
when objectively assessed with a PFT (Aaron et al., 2008). When PFTs are not often performed, 
patients are often misdiagnosed or received sub-optimal care (Walters et al., 2011). Aside from 
diagnosis, it is recommended to perform spirometry at least once a year to identify patients 
whose lung function is declining quickly (GOLD, 2014). Patients with COPD, who are current 
smokers, exhibit an accelerated decline in FEV1 (Vestbo et al., 2011). This decline could be 
detectable by frequent spirometry in family care practice for early management of the disease.  
Several documents sponsored by international organizations in respiratory medicine, such 
as the Canadian Thoracic Society (CTS), the American Thoracic Society (ATS), and the 
European Respiratory Society (ERS), the Global Initiative for Asthma (GINA), and the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) have indicated that spirometry is 
necessary for the diagnosis of OADs (Coates, 2013; Qaseem et al., 2011; GINA, 2014; GOLD, 
2014). The ATS/ERS (2005) standards advocate performing spirometry in all individuals with a 
history of exposure to cigarette smoke and/or environmental pollutants, a family history of 
COPD, or the presence of a chronic cough, sputum production, or SOB (Miller et al., 2005). 
Despite recommendations by these national and international bodies, FPs have been slow to 
adopt routine spirometry diagnosis in their clinical practice for patients with symptoms of SOB. 
Usually, inhalers are prescribed to relive symptoms without diagnostic workup. 
Little is understood about factors that limit spirometry use in family clinical practice. In 
the Canadian health care system, spirometry is almost always performed in pulmonary function 
laboratories, but not in general medicine clinics or family practice, a situation that may differ 
from that in many other health-care systems. There are several factors that may be related to the 
lower rates of use of spirometry in family practice in Canada. Gershon et al., stated that some of 
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the factors that influence the use of spirometry were age, comorbidity, and age of the family 
physician (Gershon et al., 2014). Patients with older primary care physicians were less likely to 
receive testing (Gershon et al., 2014).  Furthermore, another study in Montreal, Canada, stated 
that the lack of allocated time and training for health care professional makes the implementation 
of spirometry challenging (Saad et al., 2014).  
Early detection, accurate diagnosis, optimal evaluation, and management of airway 
obstruction are considered to be the responsibility of the primary care physician (Spyratos et al., 
2012; Saad et al, 2014). Usually, FPs are faced with the dilemma of carefully selecting patients 
for PFT in order to balance the cost and inconvenience of testing with the likely benefits. 
Nevertheless, the current GOLD and GINA guidelines require spirometry to diagnose both 
COPD and Asthma (GOLD, 2014; GINA, 2014).  In addition, health care professionals 
performing spirometry require training to perform PFT and interpret the results, to avoid missed 
diagnosis and enhance management of the disease (Levy et al., 2009). CTS offers training 
courses on how to conduct quality spirometry testing that includes knowledge of spirometers, 
understanding of the ATS/ERS standards for spirometry, quality control, patient instruction and 
basic interpretation of the results (Coates et al., 2013). The lack of spirometers in primary health 
care facilities could impair primary health care physicians from providing adequate care to 
patients with OADs.   
COPD has been defined by the GOLD as an irreversible condition, which is diagnosed by 
fixed cut-off points of FEV1/ FVC ratios. The FEV1/ FVC ratio often requires a prolonged 
exhalation time for up to 12 seconds to achieve complete lung emptying. Unfortunately, many 
elderly subjects or patients with severe respiratory diseases cannot make such vigorous physical 
effort (Bellia et al., 2008).  Lee et al., stated that that elderly are less likely to undergo pulmonary 
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function testing (Lee, Bartle, & Weiss, 2006). Alternatively, Gershon et al. stated that younger 
age might have been associated with a lower likelihood of testing because physicians did not 
suspect their younger patients had COPD (Gershon et al., 2014). 
The recent GOLD guidelines have recommended that spirometry should be performed in 
a follow-up assessment 4 to 6 weeks after discharge from the hospital to monitor changes in 
spirometric parameters (GOLD, 2014). As a response to this recommendation, performing 
spirometry using a portable spirometer in family practice may improve management for patients 
with obstructive airway diseases. Using a portable spirometer could facilitate early recognition of 
exacerbations and timely detection of treatment failure during an exacerbation.  
2.3 Reasons for lack of spirometry testing in pharmacy practice 
There are many factors associated with the lack of spirometry testing in community 
pharmacies. Cawley, Pacitti, & Warning stated that some pharmacists feel that spirometry is 
outside their scope of practice (Cawley, Pacitti, & Warning, 2011). The role of pharmacists in 
screening patients suspicious of having OADs should be acknowledged among pharmacists and 
other health care professionals. Pharmacists might be able to screen patients suspicious of having 
OADs using the micro-spirometer (Piko-6), then report patients with limited airflow to their 
primary health care physician for a complete assessment of the disease, if it was lacking. 
Currently, respiratory therapists are the main medical professionals responsible for pulmonary 
function testing in the hospital environment. Unfortunately, respiratory therapists are limited in 
their scope of practice to the pulmonary patient and many primary health care facilities lack the 
services of a respiratory therapist (Cawley, Pacitti, & Warning, 2011).  
The limited training provided to pharmacists, to perform spirometry, is another reason for 
lack of testing (Cawley, Pacitti, & Warning, 2011). In Memorial University of Newfoundland 
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and Labrador, pharmacy students are taught the basics of spirometry procedure and 
interpretation. However, the training provided is not sufficient to perform spirometry in 
community pharmacies. Students were not instructed to perform spirometry in the pharmacy due 
to the lack of studies that validated the use of spirometry in community pharmacy settings. 
Furthermore, most community pharmacies are not equipped with spirometers. Fuller et al., stated 
that many patients were motivated to participate in spirometry testing because the screening was 
free. However, it was unclear if patients would have participated if a cost had been associated 
with the screening (Fuller et al., 2012). In addition, in the current health-care environment, 
pharmacists trained in spirometry testing would most likely want to receive financial 
compensation (Cawley, Pacitti, & Warning, 2011).  
2.4 The need for portable spirometry to detect airway obstruction 
In 2000, a consensus statement from the National Lung Health Education (NLHEP) 
program recommended the development of portable spirometers that can be specifically used for 
family care or office practice (Ferguson et al., 2000). The NLHEP developed a compliance 
checklist for office spirometers based on the ATS/ERS (2005) guidelines (NLHEP, 2012).The 
CTS recommends the use of the NLHEP guidelines when choosing an office spirometer (Coates 
et al., 2013). It was expected that the new categories of these machines may lessen the burden 
and difficulty of using the sophisticated and complicated spirometers that are used in hospitals 
and PFT laboratories, where formal testing usually takes place. Since most FPs in office 
practices do not need the level of sophistication present in these more expensive machines, 
portable office-based spirometers may make spirometry more accessible and affordable for 
patients in the ambulatory setting. Currently, many lung air flow –sensing devices have been 




Table 2.1 Maneuvers for Performing the PiKo-6 Test (Steps are adapted from the device manual 
for commercial purpose) 
 
NOTE: Before you start, mount the disposable mouthpiece to the PiKo-6 
device. When the LCD display is bank, press the “Operate” button once and 
the PiKo-6 will turn on. Ignore numbers that may appear on the screen. 
 
  
STEP 1: Stand up straight with your head straight up to open your airways. 
Do not sit down or bend your head down while performing the test. Hold the 
PiKo-6 horizontally in your right hand and the LCD display pointing up. DO 







STEP 2: Bring the PiKo-6 up close to your face and press the operate button 
momentarily with your index figure. A short beep will be heard.  
 
 
STEP 3: Inhale as much air as you can to fill your lung when the second beep 
is heard and the “blow animation” appears. 
 
After the second beep, you have 10 second to start blowing.  
If the “blow animation” disappears you have to repeat STEPS 1 to 3.  
 
 
STEP 4: Place the mouthpiece in your mouth and blow as hard as you can for 





Test Results: Your lung test values for FEV1, FEV6 and FEV1/FEV6 will automatically start to 
display sequentially on the LCD.  
 
IMPORTANT: If a cough has been detected while you were blowing, or your effort was too 
short, or you had a slow start, a “!” symbol may appear next to your FEV1, FEV6, and 
FEV1/FEV6 values.  
 










The PiKo-6 stores and displays the test results; therefore, it may be a useful device to 
self-monitor development of COPD and asthma conditions. Recent studies have evaluated the 
screening utility of the PiKo-6 device and assessed the reliability of the PiKo-6 spirometer by 
comparing it with laboratory spirometers (Bemt et al., 2014; Frith et al. 2011; Wada et al., 2010; 
& Kaufmann et al., 2009). These studies were critically appraised and included in chapter 5 
(Discussion and Conclusion).  
2.5 FEV1/FEV6 replace FEV1/FVC ratio to detect airway obstruction 
Forced Expiratory Volume in 6 seconds (FEV6) has been shown to be a good surrogate 
marker for forced vital capacity (FVC). An exhalation in six seconds is easier to accomplish in 
most patients than obtaining the full FVC in laboratory setting. Many studies recommend 
replacing the FVC used in PFT spirometers with FEV6 (Nwagha et al., 2014; Perez-Padilla et al., 
2013; & Jing et al., 2009). These changes have been necessitated to minimize the measurement 
error in FVC. The measurement error frequently occurs as a result of failed attempts at full 
exhalation between 6 and 10 seconds of maximum patient effort, especially in elderly patients. 
Establishing FEV6 as the standard parameter would eliminate this uncertainty. Instead of the 
FEV1/ FVC ratio, the new FEV1/ FEV6 ratio has been proposed and validated as a parameter for 
screening and assessing obstructive airway diseases (Jing et al., 2009; Nwagha et al., 2014). Jing 
et al., systematically and quantitatively evaluated published studies that assessed FEV1/FEV6 
ratio, as a valid alternative to the FEV1/FVC ratio (Jing et al., 2009). Here, they reported that a 
reliable FVC measurement was obtained in less than 60% of spirometric measurements. 
Alternatively, another study reported that a reliable FEV6 measurement was obtained in more 
than 80% of spirometric measurements (Bellia et al., 2008; Glindmeyer et al., 1987). 
Furthermore, Perez-Padilla et al., stated that the FEV1/FEV6 ratio is a more reliable index than 
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the FEV1/FVC ratio, as FVC varies within the duration of the forced exhalation (Perez-Padilla et 
al., 2013). The FEV6 measurement creates less discomfort for the patients than FVC, especially 
in elderly subjects or patients with severe respiratory diseases (Jing et al., 2009). As a result, 
FEV6 measurements may be easier to perform than full exhalations (FVC). The NLHEP 
checklist for office spirometers compliance with NLHEP guidelines accepts FEV6 as an 
alternative for FVC (NLHEP, 2012). Although FEV6 has been validated in many studies, the 
various respiratory groups (GINA, GOLD, CTS, and ATS) have not yet released position 
statements on it. Therefore FEV1/FEV6 assessment in primary care with a micro-spirometer, such 
as the PiKo-6 portable device, may be useful in the baseline diagnostic work up of patients who 
are suspected of having an OAD. In this context, assessment of the utility of portable spirometry 
for screening in community patients in the pharmacy settings could lead to significant benefits, 
such as improving the appropriateness of diagnostic test prescription and facilitating the early 
diagnosis of asthma and COPD.  
2.6 The PiKo-6 study proposal  
The current study hypothesized that the PiKo-6, when delivered by community 
pharmacists to patients suspected to have OADs, correlates well with the results from standard 
laboratory spirometry.  
2.6.1 Research question 
In patients with inhaler prescription for the relief of shortness of breath with an unknown 
cause, do the PiKo-6 measures of lung function correlate well with the standard Pulmonary 




Population of interest: patients with inhaler prescription for the relief of airflow limitation with 
an unknown cause 
Intervention: Trained pharmacist used the PiKo-6 to measure pFEV1, pFEV6 and the pRatio 
Comparison: Laboratory specialists used the standard spirometer to measure FEV1,FVC and 
FEV1/FVC 
Objective: Correlation and validity of the Piko-6 portable spirometer compared to the 
laboratory spirometer. 
2.6.2 Research objectives 
1. To analyze the repeatability of the PiKo-6 spirometry applied at 5-minute interval in 
community pharmacy settings; 
2. To measure the accuracy of the Piko-6 lung volume measures (pFEV1, pFEV6 and the 
pRatio) by comparing it with the laboratory spirometry lung volume measures (FEV1, FVC 
and the ratio); 
3. To analyze the screening utility of the PiKo-6 spirometry by comparing physician-diagnosed 
COPD (using the laboratory spirometer) at various cut-off values of the Pre-Bronchodilator 
pRatio (pFEV1, pFEV6) for maximal sensitivity, specificity, positive predicted value (PPV), 
negative predicted values (NPV), and the area under Receiver Operating Characteristic 
(ROC) Curves. 
4. To evaluate whether bronchodilator administration modifies the concordance observed in 








Chapter 3: Methods and Materials 
3.1 Overview and study design 
The current study is a sub-study of a large research program titled “The Investigation of 
the Epidemiology of Shortness of Breath (EpiSOB) –A Public Health Approach” (Midodzi et al., 
2010). The current thesis analyzed the data collected from the EpiSOB study. The large EpiSOB 
study was conducted in Edmonton and Saskatoon between November 2008 and May 2013. To 
summarize, the EpiSOB research program seeks to identify existing care gaps in diagnosis, 
treatment, and management of patients with SOB symptoms. The EpiSOB study was conducted 
at the Epidemiology Coordinating and Research (EPICORE) center at the University of Alberta, 
Edmonton, Canada. The EpiSOB program study design, the data collection instruments and 
methods have been described in detail elsewhere (Midodzi et al., 2010). Figure 3.1 presents the 




3.2 Community pharmacy recruitment and training 
Randomly selected pharmacies (n=25) in Edmonton and Saskatoon, Canada, were invited 
to participate in the study. Standard letters of invitation were sent to the managers of all selected 
pharmacies. The letters explained the study objective, procedure, and outcomes. Of these, 12 
pharmacies responded and were enrolled for patient recruitment. At each pharmacy, a designated 
pharmacist was responsible for patient recruitment. The recruiting pharmacists were invited to 
the study center at EPICORE for two hours of training sessions. Trained physicians and study 
coordinators performed the training sessions. The sessions clarified the process of recruiting 
subjects, explaining study protocol, completing the study forms, performing the PiKo-6 
spirometry, and assessing the patient’s current medication use.  
3.3 Patient recruitment and data collection 
3.3.1. Recruitment  
Recruited patients were 18 years or older with an active prescription (dispensed within 
the past 6 months) for a Short-Acting Beta-Agonists (SABA), Short-Acting Anticholinergics 
(SAAC), Long-Acting Beta-Agonists (LABA), and/or Long-Acting Anticholinergics (LAAC), 
including combination products and inhaled steroids by a family physician. Patients who cannot 
communicate in English (unless a family member or friend can accompany the patient to the visit 
and interpret); who are unwilling or unable to come in for pulmonary function testing and a 
physical examination, were pregnant females or do not provide informed consent were excluded.  
Pharmacists used two methods to recruit patients. First, pharmacists identified patients 
attending pharmacies with new prescription or when obtaining refills for their asthma or COPD 
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medication. The second method was done via screening the pharmacy records for patients with a 
new prescriptions or refills for their asthma or COPD medication within the past 6 months. As 
part of the informed consent process, pharmacists obtained verbal consent to obtain spirometry 
tests using the PiKo-6 spirometer. In addition, pharmacists asked the patients for permission to 
contact their family physician by mail or fax to enquire about the specific condition(s) for which 
they were prescribed medication for their airway diseases. In return, family physicians would 
receive the results of the study evaluations, including PFTs. 
When a patient met the inclusion criteria for the program, the pharmacist used the 
following standard script to obtain verbal consent and allow the project office at the EPICORE 
Centre to contact the subjects by phone:   
Hi Mr/Mrs/Ms __________________ I see you are prescribed with an inhaler _______.  Were you given this medication 
for shortness of breath?.   
 If the answer is yes:   
o Are you interested in finding out more about your condition? A research program conducted at 
the U O A and U of S is interested in patients who are given this medication for SHORTNESS OF 
BREATH, and to look into the cause of shortness of breath.  
 If yes:   
o Can I provide your name and phone number to the Project office at the University of 
Saskatchewan?   
 If patient consents:  
o Pharmacist Complete Patient Screening Form and fax to the research coordinating centre at 
the EPICORE. 
For patients that were recruited via the pharmacy data base, the pharmacist called the 
patients to inform them about the EpiSOB program procedures, and asked them to participate. 
Pharmacists used the following standard script to recruit patients:  
Hi Mr/Mrs/Ms, ……..  I noticed that you filled / refilled a prescription for ___________.  I am phoning to enquire if 
you would be interested in being part of a research program.  Do you remember why you were given this 
medication?  
 (it needs to be SHORTNESS OF BREATH not cough).   
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 If the answer is SHORTNESS OF BREATH:   
o Are you interested in finding out more about your condition?  A research program conducted at 
the U of A and U of S is interested in patients who are given this medication for SHORTNESS OF 
BREATH, and to look into the cause of shortness of breath.   
 If yes:   
o Can I provide your name and phone number to the project office at the University of 
Saskatchewan?   
 If patient consents:  
Pharmacist Complete Patient Screening Form and fax to the research coordinating centre at the EPICORE. 
3.3.2. Data Collection 
During the pharmacy screening, recruited patients performed two spirometry tests using 
the PiKo-6 spirometer. The results of the two tests were used to assess the repeatability of the 
PiKo-6. However, only patients attending community pharmacies, not recruited via the pharmacy 
records, were able to perform the PiKo-6 spirometry. The PiKo-6 test was performed according 
to the manufacturer’s instruction. The procedure of performing the PiKo-6 spirometer is outlined 
in Table 2.1. 
The project office at the EPICORE Centre contacted patients by phone to inform them 
regarding the program procedures, and asked them to participate. Consenting patients were 
scheduled undergo a full set of diagnostic tests including PFT, blood, and urine. The PFT test 
was performed according to the ATS/ERS guidelines. The process of the spirometry testing is 
explained by Miller el al. “Standardisation of spirometry” (Miller et al., 2005).  
Blood tests included tests for heart failure biomarkers, such as Brain natriuretic peptide 
(BNP). When patients attended to perform their diagnostic tests, they were also asked to 
complete a survey to document self-reported medical history, physical symptoms, and baseline 
demographic information. A copy of the questionnaires and laboratory results is attached in 
Appendix 1. Although the EpiSOB program did not intervene at any point during the study, 
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diagnostic information and the findings from this program were relayed to the patient and the 
pharmacist.  
3.3.3 Diagnosis 
Three members of the EpiSOB program were physicians who specialise in respiratory 
diseases, including Dr. Dilini Vethanayagam, Dr. Irvin Mayers, and Dr. Brian Rowe (Midodzi et 
al., 2010). All three physicians were blinded to the previous diagnosis history of the pationts, if 
they ever had a diagnosis for SOB. These physicians discussed the rationale for collecting data 
from physical examinations.  Although it was agreed that a physical examination combined with 
the PFT would be the “gold standard” for diagnosis, its routine use for the purposes of the 
EpiSOB study would have been labour-intensive. The investigators decided to use diagnostic 
algorithms that were developed according to national guidelines (GINA, 2008; GOLD, 2008)  
and approved by the consensus of the three study physicians. The standard diagnostic algorithm 
for the diagnosis of asthma and COPD is presented in Figure 3.2 (Midodzi et al., 2010).  
The study coordinator reviewed all test results and patient interview forms for definite 
diagnosis of asthma or COPD, using the diagnostic algorithms developed by the physicians. For 
patients with no definite diagnosis for asthma or COPD, a methacholine challenge test was 
arranged to determine the presence or absence of airway hyper responsiveness.  
Patients whose diagnosis remained unclear after the methacholine test, had their 
information and test results reviewed by the three physicians for asthma or COPD adjudication. 
A diagnosis was upheld if there was 2/3 agreement among physician reviewers. Any patient with 
an unclear BNP result (100 pg. /mL) was referred to see a cardiologist consultant for further 
clinical evaluation. Finally, the study coordinator completed a final diagnosis form that included 
the final diagnosis and the method used for diagnosis (Appendix 2). 
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BNP is a cardiac neurohormone secreted by the cardiac ventricles in response to 
ventricular wall tension, pressure overload, and increased volume expansion. BNP levels have 
been used to follow improvement after Heart Failure therapy. A high BNP level estimates the 
risk of HF exacerbations (Shiber & Santana, 2006). The current Canadian Cardiovascular 
Society guideline to manage heart failure recommends testing of BNP levels to rule out heart 
failure diagnosis (McKelvie et al., 2013). Moreover, BNP testing is recommended by the 
Canadian Heart Failure consensus guidelines to help differentiate between shortness of breath 
due to lung diseases or heart failure, where BNP levels are markedly elevated (McKelvie et al., 
2013). In the EpiSOB study, all patients who had BNP value greater than 100 pg./mL were 






3.4 Outcome measures  
To address the objectives of the current study, the analysis presented in the thesis was 
completed in the following five steps: 
1. The demographics of subjects who volunteered or declined to perform the PiKo-6 spirometer 
were presented; 
2.  Intraclass correlation coefficient was calculated to assess the repeatability of the PiKo-6 
spirometer;  
3. The standard laboratory spirometer (pre and post- bronchodilator) data was presented in 
relation to differences across physician diagnosis;  
4. The Intraclass Correlation coefficient and Bland-Altman analysis were presented to assess 
the validity of the PiKo-6 spirometer, obtained from the pharmacist, compared with the 
laboratory spirometer test, obtained by the laboratory specialist. 
5. The screening utility of the PiKo-6 pFEV1/pFEV6 were assessed by examining the sensitivity, 
specificity, PPV, NPV at various cut-off values against the physician-diagnosis of COPD 
(based on standard spirometry). 
3.5 Data analysis 
3.5.1 Sample size calculation  
The EpiSOB study was powered at 90% to determine a 70% prevalence of obstructive 
airway diseases (mainly asthma and COPD) in community patient with SOB.  The sample size 
was estimated using EPI INFO v 6.04 for population surveys. Assuming that 70% prevalence of 
OADs in patients prescribed inhalers from family practice to relieve symptoms of SOB, a total of 
323 patients will be required for a precision of ±5% at a confidence level of 95%. To account for 
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missing information, the sample size has been inflated to 350. The main EpiSob study recruited 
327 patients at completion. All patients performed the standard laboratory spirometry. Of these, 
234 patients were recruited in-person as the patients attend community pharmacies. Only 63 of 
the 234 patients volunteered to perform the PiKo-6 study.  
Post-hoc justification for sample size adequacy used in the PiKo-6 analysis 
a) Repeatability analysis 
  To assess the PiKo-6 repeatability analysis, we assess if there is a significant correlation 
(ρ) in measures taken at two time points (Test-1, and Test-2). Using the Fisher’s Z-
transformation, we assume delta (δ) is the relevant difference between the pRatio from Test1 and 
the pRatio from Test2. The test of hypothesis is the following: Ho: δ=Z ρ which has a standard 
error of S.E (D) = sqrt (1/(1-n)), where D is the estimate of ρ, Z is the fisher Z-equation, and n is 
the sample size required. The approximate sample size required to detect a correlation of 0.6, 0.7, 
0.8, and 0.9 are 25, 17, 12 and 8 respectively (Bland, 2000, P344). The sample size would 
produce a 5% significant level and 90% power. Thus, there was a sufficient sample size for the 
result presented in the thesis under the correlational analysis (n=63). We chose to use the pRatio 
as a measure for the analysis because it is a composite of pFEV1 and pFEV6.    
b)  Validation analysis 
In the validation analysis, we assess if the PiKo-6 spirometry measures correlate with the 
standard laboratory spirometry measures. In our post-hoc sample size calculation, the estimate 
between pRatio (pFEV1/pFEV6) and FEV1/FVC was calculated. The measurements variance 
(VB) obtained between the PiKo-6 and the standard laboratory spirometers; and within 
individual patient variance (VI), obtained within the 63 patients, were: VB=0.026, and VI=0.011.  
Therefore, the estimate of the intraclass correlation or pulled variance between the PiKo-6 and 
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laboratory spirometers is 0.0262 (Bland, 2000, p.345). Assuming the maximum of the PiKo-6 
pRatio from the two test was used, and assuming a 0.1 (or =10%) difference in the FEV ratio is a 
clinically relevant difference, the number of patients required would be approximately 55. This 
sample size would produce a 90% power and at 5% significance level. As a result, we can infer 
that our sample size of 63 subjects is adequate to assess the validity of the PiKo-6 spirometer.   
3.5.2 Statistical analysis  
Data was entered into the database using unique non-identifying numbers. The 
information was password protected. Before analysis was performed, data were cleaned, coded 
and entered into Statistical Package for the Social Sciences (SPSS) version 21.0 (IBM Corp., 
Armonk, NY) for analysis. The unclear or incomplete survey items were flagged for queries.  
These were brought to the attention of the research data manager where each item was discussed 
and a decision concerning its eligibility and entry was made.   
The database was analyzed using descriptive statistics for continuous variables and 
frequencies for categorical variables. Univariate analysis was used to compare patients who 
performed or declined to perform the PiKo-6 spirometry with respect to demographics as well as 
prior history of comorbidities and diagnostic tests. Continuous variables were compared using 
the independent sample t-test while the categorical variables were assessed using a contingency 
table with chi-squared tests. All statistical tests were performed with an alpha significance level 
of 0.05.   
One-way analysis of variance (one-way ANOVA) was used to evaluate the differences 
between the components of the pulmonary function test and their effect on asthma, COPD, or 
other airway diseases. The agreement and relationship between the two repeated measures using 
the PiKo-6 spirometer were analysed by calculating the intraclass correlation coefficient (ICC) 
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(2,1) and the Pearson correlation coefficient (r), respectively; the results were represented 
graphically using correlation graphs (Fleiss, 1986). The ICC (2, 1) test is used when each subject 
is measured by each rater, and raters are considered representative of a larger population of 
similar raters.  
The variables of the pFEV1, pFEV6, and pRatio were compared to FEV1, FVC, and 
FEV1/FVC for each subject using a paired t-test. A high correlation does not automatically imply 
good agreement between PiKo-6 and lab spirometry. Bland and Altman explained that 
correlation alone does not show good agreement and recommended the use of Bland-Altman 
plots (Bland & Altman, 1986). As a result, we used reliability analysis of Bland-Altman plots to 
assess the agreement between the Piko-6 and standard spirometry (Bland & Altman, 1986).  
When using the reliability analysis method of Bland-Altman to assess the agreement of 
the PiKo-6 spirometer with the standard laboratory spirometer, the patients’ best expiratory flow 
data (i.e., highest of pFEV1 and pRatio values) obtained from Test 1 and 2 were used for 
assessing bias and limits of agreement with laboratory spirometry. According to the ATS/ ERS 
guidelines, the patients’ best expiratory flow data is recommended to represent the patient’s best 
effort at the time of testing (Miller et al., 2005). The Bland-Altman analysis suggest that, a 
clinical test instrument (in this case PiKo-6 spirometry) is valid if the deviation from the gold 
standard (in this case, laboratory spirometry)  is not significant enough to cause problems in 
clinical interpretation, 95% of the values are expected to lie within ±2SD. 
Bias and limits of agreement were calculated. The results were illustrated using a scatter 
plot. To calculate the limits of agreement, the mean difference (đ) and the standard deviation of 
the differences (s) were computed. Difference was calculated by subtracting the standard lab 
spirometry reading from the PiKo-6 reading, or from the difference between the first and second 
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PiKo-6 readings. The standard error= √3�2/� , where n is the sample size (Bland & Altman, 
1986). The limits of agreement = đ – 2s to đ+2s (Bland & Altman, 1986). The 95% confidence 
interval for the bias was calculated by finding the appropriate point of the t distribution with 1 − 
n degrees of freedom; on most tables the columns marked 5% or 0.05, and then the confidence 
interval was from the observed value minus t standard errors to the observed value plus t 
standard errors (Bland & Altman, 1986).  
Receiver Operating Characteristic curve analysis  
Receiver operating characteristic (ROC) curves are used in medicine to determine a cut-
off value for a clinical test. The ROC curves were used to determine the most suitable cut-off 
value for the FEV1/FEV6 ratio. The ROC curve analysis of the PiKo-6 spirometry test aims to 
find a cut-off value for the pFEV1/pFEV6 that will minimize the number of false positives and 
negatives which is the same as maximizing the sensitivity and specificity. However, it is 
important not to miss detecting a patient with pulmonary disease, therefore it is more important 
to maximize sensitivity (maximizing true diagnostic positives) than to maximize specificity 
(maximizing true diagnostic negatives). If the patient’s test falls below the recommended cut-off 
value, subjects would be suspected to have an OAD. The ROC curve is a graph of sensitivity (y‐
axis) vs. 1 – specificity (x-axis). The standard laboratory (pre- bronchodilator FEV1/FVC) and 
the PiKo-6 (pFEV1/pFEV6)  were compared against physician diagnosed COPD. The physician 
diagnosed COPD was based on the standard laboratory spirometry (post-bronchodilator FEV1 
<80% predicted together with an FEV1/FVC <70%).  
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3.6 Ethics and Confidentiality  
The study protocol and consent forms were approved by the University of Alberta Health 
Research Ethics Board and the Biomedical Research Ethics Board at the University of 
Saskatchewan. Patients signed a consent form to participate in the study. In addition, the patients 
consented to release their medication information from the Alberta NETCARE system 
(ww.albertanetcare.ca). Each study participant was given a study number by the pharmacy. The 
coordinating office received data from the pharmacies with study number and patient initials 







Chapter 4: Results 
This chapter presents the study findings in three sections. The first section describes the 
demographics and baseline characteristics of the study sample, such as weight, co-morbidities 
and socio-demographics. The second section covers the repeatability of the PiKo-6, variation in 
repeated measurement on the same subject. In addition, the validity between the PiKo-6 
spirometry data and standard laboratory testing was assessed. The last section explains the 
sensitivity and specificity of the PiKo-6 spirometry in relation to physician diagnosis of COPD in 
patients with SOB. 
4.1 Baseline characteristics 
  A total of 475 subjects were contacted to participate in the study (Figure 4.1), of whom 
241 subjects were recruited via the data base of the pharmacy and 234 subjects were recruited as 
they attended community pharmacies. Of the subjects who attended community pharmacies, 63 
subjects performed both the PiKo-6 and the standard laboratory pulmonary function test (PFT) 




Figure 4.1 Flow chart of subject recruitment and selection. 
To assess sampling bias, we investigated whether the baseline characteristics of the 
patients that performed PiKo-6 were similar to the patients who declined to perform the PiKo-6. 
Table 4.1 shows baseline and clinical characteristics of the subjects who attended community 


















Table 4.1 Assessing the differences in sample characteristics of the patients who volunteered 
verses those who declined to perform the PiKo-6 spirometry in community pharmacies.   





Age, yrs: Mean (SD)  53.9 (15.3) 54.1 (19.4) 0.936 
Sex, Male: n (%) 33 (52.4) 40 (44.9) 0.366 
Average BMI: Mean (SD) 31.9 (7.4) 29.4 (9.3) 0.087 
Prior History of Asthma: n (%) 38 (60.3) 55 (61.7) 0.408 
Prior History of COPD: n (%) 11 (17.5) 11 (12.4) 0.379 
Caucasian: n (%) 47 (74.6) 76 (85.4) 0.095 
Smoking: n (%) 12 (19.0) 14 (15.7) 0.593 
Allergies: n (%)                43 (68.3) 60 (67.4) 0.913 
Diabetes Type 2: n (%) 7 (11.1) 9 (10.1) 0.843 
CAD: n (%) 5 (7.9) 11 (12.4) 0.381 
Hypertension: n (%)         24 (38.1) 25 (28.1) 0.194 
High Cholesterol: n (%) 14 (22.2) 25 (28.1) 0.415 
Prior Heart Failure: n (%) 1 (1.6) 1 (1.1) 0.805 
Current Depression: n (%) 16 (25.4) 28 (31.5) 0.417 
MRC Dyspnea Scale: Mean (SD) 2.2 (1.12) 1.9 (0.82) 0.082 
Prior PFT: n (%) 31 (49.2) 47 (52.8) 0.662 
Prior Chest x-ray: n (%) 30 (47.6) 42 (47.2) 0.598 
Prior Echo: n (%) 8 (12.7) 14 (15.7) 0.601 
Prior ECG: n (%) 27 (42.9) 34 (38.2) 0.564 
Prior Methacholine: n (%) 0 (0) 2 (2.2) 0.231 
Previously given a diagnosis for SOB 
symptoms: n (%)                        






Systolic (mean) 125.92 123.34 0.522 
Diastolic(mean) 76.79 76.43 0.884 
*Significant Level P < 0.05. 
SD: Standard Deviation, Yrs: years; COPD: Chronic Obstructive Pulmonary Disease; CAD: 
Coronary Artery Disease; MRC: Medical Research Council; PFT: Pulmonary Function Test; 
Echo: Electrocardiogram; ECG: Echocardioraphy.    
§Subjects attending community pharmacies who declined to perform PiKo-6 but agreed to 






As noted from Table 4.1, there was no major statistically significant difference between 
patients who volunteered or declined to perform the PiKo-6 spirometry in pharmacy settings. 
Also, there was no statistically significant difference observed when patients who were recruited 
from the pharmacy setting (n=234) were compared to patients who were identified in the 
community setting through the use of the pharmacy databases (n=241).  The sample 
characteristics of the patients who attended the community pharmacies and patients in the 
community (recruited via the pharmacy records) are summarized in Appendix 3.    
The demographics of the patients who volunteered to perform the PiKo-6 were the 
following: 52.4 % were men, and the median age was 50.2 years. The mean ± Standard 
Deviation (SD) age of the sample was 53.9 ± 15.3 years, with a mean BMI of 31.9 ± 7.40 kg/m2. 
Participants were primarily Caucasian (74.6%). Most of the patients suffered from allergies 
(68.3%), but only 19.0% of the patients were current smokers. The majority of the volunteers 
had a history of Asthma (60.3%), but only 17.5% had a history of COPD. 
The most common self-reported comorbidities amongst the population were hypertension 
(38.1%), depression (25.4%), high cholesterol (22.2%), and Type 2 Diabetes (11.1%); 
alternatively, coronary artery disease and HF were reported at 7.9% and 1.6%, respectively. 
About half of the patients (54%) that perform the PiKo-6 in the pharmacy setting stated that they 
had a previous diagnosis for their SOB symptoms by their family physician. Of the 63 patients 
that performed the PiKo-6, 42.9% were diagnosed with asthma and 10% were diagnosed with 
COPD. Furthermore, subjects were asked “Have you ever had any of the following tests for your 
SOB symptoms?”. The most common reported tests were pulmonary function tests (49.2%), 
chest x - rays (47.6%), electrocardiograms (42.9%), and echocardiographies (12.7%).   
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The Medical Research Council (MRC) scale measures disability caused by 
breathlessness. It consists of five grades: grade 1, “Not troubled by breathlessness except on 
strenuous exercise”; grade 2, “Short of breath when hurrying or walking up a slight hill”; grade 
3, “Walks slower than contemporaries on the level because of breathlessness, or has to stop for 
breath when walking at own pace”; grade 4, “Stops for breath after about 100 m or after a few 
minutes on the level”; grade 5, “Too breathless to leave the house, or breathless when dressing or 
undressing” (Stenton, 2008).  The majority of patients (63.5%) reported dyspnea scores of 1 and 
2, whereas 36.5 % of the enrolled patients reported dyspnea scores from 3 to 5 that they fulfilled 
the criteria for referral to a hospital-based rehabilitation program. 
4.2 Repeatability of the PiKo-6 
The repeatability of PiKo-6, variation in consecutive measurement on the same subject, 
was explored. Patients performed two tests using the PiKo-6 spirometry, within a five minute 
interval, to measure the repeatability coefficient. There was a strong correlation between the first 
and second Piko-6 measurements of pFEV1 (r = 0.835, P < 0.001; Figure 4.2) and pFEV6 (r = 
0.872, P < 0.001). There was a weaker but significant correlation between the first and second 
Piko-6 measurements of pRatio (r = 0. 664, P < 0.001; Figure 4.3). ICC were:  0.83 (p <0.001) 
for pFEV1, 0.87 (p <0.001) for pFEV6, and 0.61 (p <0.001) for pRatio. These values show a 
strong correlation between the PiKo-6 consecutive measurements as suggested by the Fleiss, 
John Wiley & Sons, 1986 threshold values. Mean (± SD) of PiKo-6 spirometry (FEV1, FEV6, 




Figure 4.2 The correlation of pFEV1 spirometry measured with the PiKo-6 in the first 





Figure 4.3 The correlation of pRatio measured with the PiKo-6 in the first reading 









Table 4.2 Mean (± SD) of PiKo-6 spirometry (FEV1, FEV6, and Ratio) and Intraclass 
Correlation coefficient.  






















0.74 – 0.90 
(n= 63) FEV6, Liters  2.47±1.42  2.57±1.36  0.87 0.80 – 0.92  






Asthma  FEV1, Liters  1.75 ±1.23  1.84 ±1.00  0.72 0.78 - 0.86 
(n=26)  FEV6, Liters  2.71 ±1.45  2.93 ±1.39  0.76 0.55 – 0.88 
 FEV1/FEV6   0.65± 0.20  0.66 ±0.17  0.94 0.87 – 0.97 
         
COPD  FEV1, Liters  1.31 ±0.75  1.24 ±0.66  0. 86 0.67 – 0.95 
(n=19 ) FEV6, Liters  2.00 ±1.09    2.01 ±0.95  0.90 0.75 – 0.96 
 FEV1/FEV6   0.65 ±0.10  0.61 ±0.13  0.70 0.36 – 0.89 
         
Others  FEV1, Liters  1.99 ±1.21  1.96 ±1.19  0. 96 0.88 – 0.97 
(n=18) FEV6, Liters  2.62 ±1.61  2.62 ±1.57  0.92 0.71 – 0.97 
 FEV1/FEV6   0.75 ±0.15  0.77 ±0.18  0.13 -0.33 – 0.57 
FEV₁: Forced Expiratory Volume in one second, FEV6: Forced Expiratory Volume in six 






4.3 Validity of the PiKo-6 
All patients who performed the PiKo-6 spirometry were referred to perform a laboratory 
PFT. In all cases, the standard laboratory PFT was performed. The median of the time difference 
between PiKo-6 spirometry and standard laboratory spirometry was 35 days (interquartile range: 
18 – 77). We compared the results of the pre and post bronchodilator (BD) PFT (spirometry, 
lung volumes, and diffusion capacity) in relation to differences across physician diagnosis. Mean 
(± SD) of percent (%) predicted pre-BD laboratory PFT results are shown in Table 4.3 and post-














Table 4.3:  Mean (± SD) of percent (%) predicted pre- bronchodilator laboratory Pulmonary 
Function Test  









FVC,  94.38±20.29 101.11±15.97 81.94±15.68 97.77±24.73 .004 
FEV1,  80.36±22.84 87.46±15.57 59.31±14.67 92.33±24.38 .000 
*FEV1/FVC ratio, % 68.17±11.62 70.30±08.79 57.05±10.49 76.83±06.19 .000 
PEF 96.33±28.10 101.22±26.43 74.21±22.05 112.55±21.80 .000 
VC 96.77±20.13 103.26±14.57 85.36±18.19 99.44±24.44 .008 
TLC 103.38±17.24 105.07±15.65 107.78±18.06 96.27±17.30 .102 
RV 100.04±36.20 91.61±30.71 129.73±31.78 80.88±29.01 .000 
RV/TLC 95.04±28.63 85.23±22.22 119.84±22.03 83.05±27.63 .000 
FRC PL 98.42±23.73 98.46±21.27 110.89±25.20 85.22±18.89 .003 
DLCO 93.19±22.20 97.15±17.52 79.36±20.72 102.05±23.88 .003 
VA,  88.88±15.16 93.92±12.84 80.68±14.71 90.27±15.83 .011 
DLCO adjusted for 
VA 
97.84±21.07 99.53±15.45 86.31±21.26 107.55±23.16 .006 
BD: Bronchodilator, FVC: Forced Vital Capacity, FEV₁: Forced Expiratory Volume in one 
second, PEF: Peak Expiratory Flow, VC: Vital Capacity, TLC: Total Lung Capacity, RV: 
Residual Volume, FRCPL: Functional Residual Capacity Plain phase, DLCO: Diffusing 
Capacity, VA: Alveolar Volume 
* Values base on Mean (± SD) of actual pre-bronchodilator laboratory PFT (spirometry)  
-Bolded values were available for post-bronchodilator and used in the diagnosis of asthma and 
COPD by ATS and ERS guideline, and in aide of physician assessment. The data are presented 
in Table 4.4 
 
Table 4.4:  Mean (± SD) of percent (%) predicted post- bronchodilator laboratory Pulmonary 
Function Test 









FVC 95.12±95.12 99.23±26.06 87.15±16.11 97.61±23.36 .191 
FEV1 83.60±24.70 89.19±24.60 65.31±14.28 94.83±23.74 .000 
*FEV1/FVC ratio, % 69.98±12.71 71.46±12.74 59.26±09.57 79.17±05.69 .000 
PEF 99.68±30.28 102.15±33.87 81.42±16.79 115.38±26.76 .002 
FVC: Forced Vital Capacity, FEV₁: Forced Expiratory Volume in one second, FEV6: Forced 
Expiratory Volume in six seconds, PEF: Peak Expiratory Flow. 






To assess the validity of the PiKo-6 spirometer, we compared pFEV1, pFEV6, and pRatio 
with pre-BD FEV1, FVC, and FEV1/FVC, respectively. Because the PiKo-6 tests were conducted 
in community pharmacy settings, the pharmacists did not use bronchodilators when obtaining 
PiKo-6 measurements. A two-sided, paired t-test was used to assess the differences between the 
PiKo-6 and laboratory spirometers. Differences were considered statistically significant at P < 
0.05. There was a statistically significant, moderately positive correlation between measurements 
of pFEV1 by PiKo-6 and FEV1 by laboratory spirometry (r = 0.63, P < 0.001; Figure 4.4);  and 
pFEV6 and FVC (r = 0.66, P < 0.001); and between measurements of pRatio and FEV1/FVC  (r = 








Figure 4.4 The correlation of pFEV1 (Litres) measured with the PiKo-6 compared to the 










Figure 4.5 The correlation of pFEV1/pFEV6 measured with the PiKo-6 compared to the 








Bland-Altman plots were used to compute the agreement between the Piko-6 and 
standard lab spirometry.  The difference against the mean for the pFEV1 (Figure 4. 6) and the 
pRatio (Figure 4.7) indicate that the difference between the PiKo-6 spirometry and the laboratory 
spirometry is not significant enough to cause problems in clinical interpretation. PiKo-6 bias 
(95% CI) was assessed against laboratory spirometry for pFEV1 -0.65 (-0.79; 0.01; pValue 
<0.001) and pRatio -0.04 (-0.08; 0.01, pValue=0.02). The clinical limits of agreement as 
measured by the average residual difference from the laboratory PFT spirometry were: pFEV1 (-
1.17 to 2.47 litres), pFEV6 (-1.26 to 3.14 litres), and pRatio (-0.33 to 0.24). PiKo-6 bias (95% CI) 








Figure 4.6 Bland and Altman Plot showing the difference against mean for the pFEV1 
(Litres) measured by the PiKo-6 spirometer compared to the FEV1 (Litres) measured by 








Figure 4.7 Bland and Altman Plot showing the difference against mean for the 
pFEV1/pFEV6 measured by the PiKo-6 spirometer compared to the FEV1/FVC measured 
by the laboratory spirometer (pre-bronchodilator).   
 
 






Table 4.5  PiKo-6 bias (95% CI) and limits of agreement with standard laboratory spirometry.  
    
Standard PFT Lab Spirometry 







§Maximum effort (from PiKo-6 





 ǂBias (95%CI) 
 
All patients pFEV1  0.629  -0.65(-0.79; 0.01)  -1.17 to 2.47 (L) 
(n=63) pFEV6  0.658  -0.94(-1.22;-0.18)  -1.26 to 3.14 (L) 




Asthma pFEV1  0.600  0.74(0.37; 1.11)  -1.06 to 2.54 (L) 
 (n=26)  pFEV6  0.677  0.89(0.48; 1.30)  -1.11 to 2.89 (L) 
 pRatio  0.559  0.00(-0.06; 0.06)  -0.15 to 0.28 
        
COPD pFEV1  0.289  0.31(-0.12; 0.73)  -1.43 to 2.04 (L) 
(n=19) pFEV6  0.426  0.81(0.28; 1.34)  -1.63 to 2.94 (L) 
 pRatio  0.342  -0.11(-0.17;-0.06)  -0.35 to 0.12  
        
Others pFEV1  0.712  0.89(0.42; 1.36)  -0.96 to 2.74 (L) 
(n=18) pFEV6  0.668  1.16(0.48; 1.83)  -1.48 to 3.80 (L) 
 pRatio  0.441  -0.03(-0.34;-0.20)  -0.31 to 0.26 
FEV₁: Forced Expiratory Volume in one second, FEV6: Forced Expiratory Volume in six 
seconds.  
ǂ For interpretation, refer to ‘Statistical methods for assessing agreement between two methods of 
clinical measurement’ (Bland & Altman, 1986). 
*Small limit of agreement (within ±2SD) indicate a high agreement of PiKo-6 with standard 
laboratory spirometry values. The difference within these limits of agreement would not be 
clinically important.  
§Patient’s maximum effort performed from PiKo-6 Test 1 & 2 was used for the assessment of 
agreement with the standard laboratory spirometry.  
65 
 
4.3.1 Sensitivity and specificity analysis in patients with COPD 
It is easier to screen for COPD than asthma or other chronic lung diseases, because 
COPD diagnosis does not require reversibility testing which can only be assessed with post-
bronchodilator administration. This is usually not available in community settings. The GOLD 
guidelines recommend post BD of FEV1/FVC < 0.70 as the cut-off value required to diagnose 
COPD (GOLD, 2014). Diagnostic accuracies of the standard laboratory FEV1/FVC and the 
PiKo-6 pRatio were summarized by calculating sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and the area under the ROC curve (ROC-AUC).  
The sensitivity and specificity of the laboratory spirometer pre BD FEV1/FVC < 0.70 
offered optimal sensitivity (89%) and specificity (72%). On the other hand, the sensitivity and 
specificity of the laboratory spirometer post BD FEV1/FVC ≤ 0.70, which is the recommended 
cut off value by ATS/ERS guidelines, offered sensitivity (92%) and specificity (73%) when 
compared with physician diagnosed COPD. The use of bronchodilator slightly improved the 
sensitivity and specificity values.  
The predictive power of the PiKo-6 pRatio score was calculated using different cut-off 
values. As mentioned earlier, the pharmacists did not use bronchodilators when obtaining PiKo-6 
measurements because the PiKo-6 tests were conducted in community pharmacy settings. The 
sensitivity and specificity of the PiKo-6 spirometer pRatio ≤ 0.70 offered sensitivity (52%) and 
specificity (77%). Alternatively, when raising the cut-off value of the PiKo-6 pRatio to ≤ 0.80, 
the sensitivity was 84% and the specificity was 50%. Raising the cut-off value of the PiKo-6 
pRatio to ≤ 0.80 improved the sensitivity of the PiKo-6 spirometer. The sensitivity, specificity, 
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PPV, and NPV are presented for the pRatio and both pre and post FEV1/FVC at different cut-off 
values in Table 4.6.  
In Figure 4.8, the diagnostic accuracy of the PiKo-6 FEV1/FEV6 (pRatio) in 
discriminating between subjects with or without COPD, as summarised by the ROC-AUC value, 
was 0.70 (95% CI= 0.56, 0.84). On the other hand, the diagnostic accuracy of the standard 
spirometer pre BD FEV1/FVC, as summarised by the ROC-AUC value, was 0.90 (95% CI= 0.81, 
0.98).   
The GOLD guidelines recommend spirometry value of FEV1/FVC ≤ 0.70 to diagnose 
COPD (GOLD, 2014). To use the PiKo-6 for screening purposes in community settings, we 
recommend raising the cut-off value of the PiKo-6 ratio to ≤ 0.80. According to the ROC curve 
(Figure 4.8) and the scatter plot (Figure 4.9), the best combination of specificity and sensitivity 
corresponded to a PiKo-6 pRatio score of 0.80. Only patients with a pRatio ≤ 0.80 could be 
referred to perform standard laboratory spirometry to confirm airflow obstruction. Although 
raising the cut-off value of the pRatio to ≤ 0.80 would increase the false positive rates (from 23% 
to 50%), the selected patients could have other OADs that require a standard laboratory PFT to 
confirm their diagnosis. Figure 4.9 show the cut-off values for the pRatio and pre-BD FEV1/FVC 







Table 4.6 Diagnostic accuracy of the PiKo-6 (pRatio) and Laboratory spirometry (FEV1/FVC) 
when changing cut-off values and bronchodilator usage (assessed against physician diagnosed 
COPD).   

















Sensitivity 0.52 0.89 0.92 0.84 1 1 
Specificity 0.77 0.72 0.73 0.50 0.25 0.25 
PPV 0.50 0.58 0.50 0.42 0.36 0.36 
NPV 0.79 0.94 0.97 0.88 1 1 
BD: bronchodilator, FEV₁: Forced Expiratory Volume in one second, FVC: Forced Vital 
Capacity, pFEV₁: PiKo Forced Expiratory Volume in one second, pFEV6: PiKo Forced 
Expiratory Volume in six seconds, PPV: Positive Predictive Value, NPV: Negative Predictive 
Value 
a: The measure used to diagnose COPD according to the GOLD guidelines (GOLD,2014) 




















Figure 4.8 The receiver operating characteristic (ROC) curve for the Piko-6 pRatio versus 
the standard Laboratory pre BD FEV1/ FVC (Assessed against Physician-diagnosed 









Figure 4.9 Different cut off values for the pRatio (pFEV1/pFEV6) measured with the PiKo-6 
compared to the FEV1/FVC Laboratory Spirometry (pre-bronchodilator).  
The PiKo-6 cut-off values of the pRatio (x-axis) and Laboratory spirometry cut-off values of 
FEV1/FVC (y-axis) are outlined. By raising the cut-off value of the PiKo-6 from 0.70 to 0.80, we 
include more patients who are suspected of having obstructive airway diseases. After performing 
laboratory spirometry, physicians concluded that most of these patients are diagnosed with 












Chapter 5: Discussion and Conclusion 
 
5.1 Main findings 
In this thesis, the results of the PiKo-6 spirometer were compared with standard 
pulmonary function tests. In addition, the PiKo-6 was assessed against physician diagnosed 
COPD to calculate sensitivity, specificity, PPV, and NPV. The comparison shows that the use of 
the PiKo-6 spirometry could be a method for preselecting subjects for further diagnostic work up 
of patients who, according to their pharmacist, may have chronic airflow obstruction. The results 
suggest that the PiKo-6 correlates well with standard laboratory spirometry; thus it could be used 
to screen for OADs at community pharmacies. We used a screening approach that consisted of a 
screening questionnaire, followed by a pocket spirometry assessment, then a standard laboratory 
spirometry. This pharmacy screening approach may improve efficiency of early detection and 
management of OADs. Nevertheless, the final diagnosis of the OAD will be completed by the 
family physician.   
Taking into account that the NPV of the PiKo-6 spirometry was 88%, a subject with a 
negative PiKo-6 spirometry test (pre-BD pRatio≥ 0.80) is unlikely to show airflow obstruction in 
subsequent diagnostic spirometry testing. However, the PiKo-6 spirometry should not be used to 
diagnose COPD. In our study, we suggest choosing a high cut-off value of 80% for the pRatio in 
patients with SOB symptoms to avoid missing airflow limitation, thus accepting a high rate of 
false positive results. We suspect that most of the patients, who showed airflow limitation when 
tested with the PiKo-6 spirometry, are at a high risk of OADs. Our results recommend patients 
with a PiKo-6 FEV1/FEV6 (pRatio) lower than 0.80 to be referred to their family physician for 
further diagnostic work up, if it was lacking.  
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5.2 Previously published studies that compared the PiKo-6 spirometry with the standard 
laboratory spirometry 
Solidoro et al., used the PiKo-6 spirometry in a community pharmacy setting; however, 
they did not compare the results of the PiKo-6 with the standard spirometry which limits the 
comparability of their results with our study (Solidoro et al., 2013). The study by Solidoro et al. 
is summarised in section 5.4 below.  
Due to the lack of studies that validate the use of the PiKo-6 spirometer in community 
pharmacy settings, we investigated studies that validated the use of the PiKo-6 in primary care 
settings. We summarized four cross sectional studies that validated the use of the PiKo-6 in 
primary care settings. Studies were conducted in Asia (Wada et al., 2010), Europe (Bemt et al., 
2014; Kaufmann et al., 2009), and Australia (Frith et al., 2011). All four studies examined the 
diagnostic accuracy of the PiKo-6 spirometer compared to laboratory spirometry. In addition, 
investigators using the PiKo-6 were given a uniform and brief training on how to use the PiKo-6 
device according to the manufacturer’s instructions.  
First, our finding that the PiKo-6 spirometer allows simple screening for OADs replicates 
the findings of a randomized cross sectional study conducted by (Frith et al., 2011). The study 
was implemented in a primary care setting to determine the accuracy of FEV1/FEV6 using the 
portable PiKo-6 spirometer to screen for COPD. Current and former smokers (> 50 years old) 
with no previous respiratory diagnosis (case finding [CF]) or with an asthma diagnosis or 
treatment (differential diagnosis [DD]) were evaluated using validated questionnaires, pre-
bronchodilator (BD) FEV1/FEV6 and pre and post-BD FEV1/FVC spirometry. The investigators 
used a study diagnosis of COPD based on GOLD spirometry criteria, post-BD FEV1/FVC of < 
0.70; In addition, they used a study diagnosis of asthma based on spirometry testing with 
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bronchodilator reversibility according to ATS/ERS guidelines. The researchers concluded that 
the PiKo-6 could optimise early referral for spirometry and improve provision of early, targeted 
interventions aimed at reducing the burden of COPD (Frith et al., 2011). The results of Frith et 
al. will be compared with the results of our study in in section 5.3. 
A second article by Wada et al. designed a cross-sectional study to investigate the 
usefulness of a combination of the portable PiKo-6 spirometer with a COPD questionnaire to 
screen patients in a primary care setting (Wada et al., 2010). The researchers included clinically 
stable outpatients attending a cardiovascular clinic and excluded patients who were <40 years 
old, those who had already been diagnosed as having COPD, and those receiving treatment for 
COPD. Patients with both a pFEV1/pFEV6 <70%, as measured on the PiKo-6, and a score of  17 
points on the International Primary Care Airways Group (IPAG) COPD questionnaire were 
assigned to the COPD group, and all other patients were assigned to the non-COPD group. 
Patients in the COPD group underwent spirometry to confirm their diagnosis. The relationships 
between pFEV1, pFEV6 and pFEV1/pFEV6, as measured by the PiKo-6, and FEV1, FVC and 
FEV1/FVC, respectively, as measured by spirometry, were assessed. Wada et al., concluded that 
combining both the PiKo-6 portable spirometer with the IPAG COPD questionnaire may be a 
useful and feasible method for identifying undiagnosed COPD patients attending a 
cardiovascular outpatient clinic. The results of Wada et al. will be compared with the results of 
our study in in section 5.3. 
The third article by Kaufmann et al., used a cross sectional study to investigate if the 
PiKo-6 could simplify and improve the diagnosis of so far undiagnosed asthma or COPD in the 
primary care setting (Kaufmann et al., 2009).The researchers included patients attending primary 
care practices and excluded patients with any known pulmonary disease. All patients whose 
74 
 
pFEV1 /pFEV6 was < 80% were told to be at risk for pulmonary obstruction and were invited to 
a standardized laboratory PFT. If the standardized PFT was ‘normal’, patients underwent a 
standardized bronchial challenge testing using methacholine to identify patients with asthma. 
Asthma was defined as follows: respiratory symptoms (e.g. cough, dyspnea or phlegm) and ≥ 
20% decline in FEV1 following methacholine provocation or an acute reversibility of > 200 ml 
FEV1 or > 15% after bronchodilation. COPD was defined as follows: reversibility of FEV1 ≤ 200 
ml or < 15% after bronchodilation. Kaufmann et al. concluded that the PiKo-6 may improve the 
detection rate of undiagnosed airflow limitation in the primary care setting (Kaufmann et al., 
2009). The results of Kaufmann et al. will be compared with the results of our study in in section 
5.3. 
Lastly, a recent cross-sectional study by Bemt et al. has presented data to assess the 
diagnostic utility of the PiKo-6 relative to a standard laboratory spirometry (Bemt et al., 2014). 
Participants were recruited as they visit a diagnostic centre for a spirometry test based on a 
referral by their GP for respiratory symptoms that may suggest underlying COPD. Bemt et al., 
included subjects who were 50 years or older and were current or former smokers. The 
investigators excluded subjects who performed a spirometry test in the previous 5 years or 
subjects who have already been diagnosed with COPD. All participants filled out a questionnaire 
about possible previous diagnoses of chronic respiratory conditions, cigarette smoking, 
respiratory medication use, previous spirometry tests, and reasons for referral by their GP. In 
addition, subjects performed standard laboratory spirometry and PiKo-6 spirometry (before and 
after administration of bronchodilator) during the same visit to the diagnostic centre. The 
investigators used a post-BD FEV1/FVC value of 0.70 from a standard laboratory spirometry as 
the gold standard to diagnose COPD. The researchers compared pre-BD pFEV1 /pFEV6, as 
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measured with the PiKo-6 spirometer, with a post-BD FEV1 /FVC from diagnostic spirometry. 
Bemt et al., concluded that the pre-BD Piko-6 spirometry seems to be able to reliably preselect 
patients for further assessment of airflow obstruction by means of laboratory spirometry (Bemt et 
al., 2014). Furthermore, they stated that the use of the PiKo-6 spirometry alone would result in 
overestimation of airflow obstruction and should not replace regular spirometry when diagnosing 
COPD in primary care settings (Bemt et al., 2014). The results of Bemt et al. will be compared 
with the results of our study in section 5.3.  
5.3 Interpretation of findings in relation to previously published work 
In summary, the previously mentioned studies indicated that the PiKo-6 may provide 
health care workers with a simple, reliable, and practical method for screening patients who 
might be at risk of OADs. In addition, the PiKo-6 could be used jointly with validated 
questionnaires as simple screening tools to increase the possibility of early and accurate 
detection of OADs. Although these studies provide us with some valuable insights, more studies 
in community pharmacies would be required to confirm the findings and elaborate on suitable 
cut-off points for the pRatio.   
5.3.1 Baseline Characteristics compared to previously published work 
Overall, the current literature appears to indicate that the PiKo-6 may be useful in 
screening patients with OADs. At the time, there was paucity of studies assessing the reliability 
of the PiKo-6 in North America. To our knowledge, this is the first study that assessed the 
validity of the PiKo-6 as a screening device in community pharmacy settings by comparing it 
with standard laboratory spirometry. In this study, we assessed airflow limitation in adults 
attending community pharmacies with SOB as an important symptom for predicting the onset of 
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OADs. Sansores et al. stated that there is a high frequency of SOB among patients with airflow 
limitation (Sansores et al., 2013). In addition, SOB has showed a statistically significant increase 
in patients with airflow limitation (Kaufmann et al., 2009). 
In the previous studies discussed in section 5.2, some studies excluded patients with 
respiratory diseases (Wada et al., 2010; Kaufmann et al. 2009); alternatively, other researchers 
included patients with respiratory diseases (Frith et al., 2011; Bemt et al., 2011). The main 
objective of our study is to assess the validity of the PiKo-6 in patients with suspected OADs. As 
a result, we included subjects who were prescribed inhalers for their SOB symptoms by their GP 
to increase the prevalence of respiratory diseases in our study. Similar to the current study, two 
studies performed both laboratory and PiKo-6 spirometry on all the subjects (Frith et al., 2011; 
Bemt et al., 2011). Wada et al. and Kaufmann et al. investigated the feasibility of using both 
COPD diagnostic questionnaires and PiKo-6 measurements to screen patients for COPD (Wada 
et al., 2010; Kaufmann et al. 2009). However, only patients at risk of pulmonary obstruction 
were invited to perform a standard PFT (Wada et al., 2010; Kaufmann et al. 2009). 
The use of questionnaires has been suggested as the simplest screening method for 
increasing early COPD detection (Sichletidis et al., 2011). Nevertheless, current COPD 
screening questionnaires may exclude patients with early stages of COPD because they require 
symptoms to be present to indicate risk. Fueller et al. found that the ‘COPD Population Screener 
Questionnaire’ excluded 75% of patients with airflow limitation. This would prevent them from 
going further to testing with spirometry (Fuller et al., 2012). Studies suggested that the absence 
of symptoms may mask a diagnosis of obstructive pulmonary diseases. Moreira stated that the 
odds of under diagnosis were significantly higher among individuals with fewer respiratory 
symptoms, suggesting that many asymptomatic patients had COPD (Moreira et al., 2014). Early 
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diagnosis for the underlying disease is poor due to patients having to perform a PFT. Spirometry 
is required to diagnose the two main diseases, asthma and COPD, underlying the symptoms of 
SOB.  
5.3.2 Repeatability of the PiKo-6 compared to previously published work 
The previous studies did not assess the repeatability of the Piko-6 spirometer. In the 
current study, patients performed two tests using the PiKo-6 spirometry to measure the 
repeatability coefficient. There was a strong correlation between the first and second Piko-6 
measurements of pFEV1 and pFEV6; however, there was a weaker but significant correlation 
between measurements of pRatio. In the current study, pharmacists were trained by pulmonary 
specialist to perform the PiKo-6 spirometer. The repeatability of the PiKo-6 showed a strong 
correlation in repeated measurements.  
5.3.3 Validity of the PiKo-6 compared to previously published work 
The validity of the Piko-6 was assessed by comparing the statistical differences in the 
results between the PiKo-6 spirometry and the standard laboratory spirometry measurements, for 
the same subjects. Frith et al., indicated that there were no statistically significant differences 
between the PiKo-6 mean pre-BD pRatio (pRatio= 0.717) or the standard laboratory spirometry 
mean ratio (FEV1/FVC= 0.721), P-value = 0.64 (Frith et al., 2011). Furthermore, Wada et al. 
(2010) stated that there was a strong correlation between measurements of pre-BD pFEV1 and 
pre-BD FEV1 (r = 0.865, P < 0.001) and between measurements of pre-BD pFEV6 and pre-BD 
FVC (r = 0.751, P < 0.001). There was a weaker but significant correlation between pre-BD 




Data from the Frith et al. and Wada et al. studies suggested a good correlation when 
compared the PiKo-6 with the standard spirometer (Frith et al., 2011; Wada et al., 2010). In the 
current study, there was a statistically significant, moderately positive correlation between 
measurements of pre-BD pFEV1 and pre-BD pFEV1 (r = 0.63, P < 0.001); pre-BD pFEV6 and 
pre-BD FVC (r = 0.66, P < 0.001); and between measurements of pre-BD pRatio and pre-BD  
FEV1/FVC  (r = 0.58, P < 0.001). This may suggest that, trained pharmacists succeeded in 
performing the PiKo-6 spirometry in community patients with SOB symptoms. To improve the 
correlation between Piko-6 and laboratory spirometers, we suggest that future studies should 
concentrate on training pharmacists on performing portable spirometry.   
5.3.4 The PiKo-6 FEV1/FEV6 Cut-off values compared to previously published work 
Previous studies have suggested different cut-off values for the pRatio. The researchers 
chose the following values to detect airflow obstruction in primary care settings: <0.73 (Bemt et 
al., 2014), <0.70 (Wada et al., 2010) and <0.75 (Frith et al., 2011). In our study, we suggest the 
use of pre-BD pRatio <0.80 as the cut-off value to indicate airway diseases. This value has been 
recommended as the preferred alternative for post-BD FEV1/FVC <0.70 as suggested by the 
guideline diagnosis (Kaufmann et al., 2009).  
Studies suggest further investigation of the cut-off values of the pRatio (Sichletidis et al., 
2011; & Wada et al., 2010).  As a screening tool, we have chosen the high cut-off value of 80% 
for the pRatio for three reasons. The first is to ensure that we have included a maximal amount of 
patients with airflow limitation. As a result, we accept the possibility of a high rate of false- 
positive results because it is more important to include patients with obstructive diseases than to 
exclude patients that do not have obstructive diseases. Although raising the cut-off value of the 
79 
 
pRatio to ≤ 0.80 would increase the false positive rates (from 23% to 50%), the selected patients 
could have other OADs that require a standard laboratory PFT to confirm their diagnosis. The 
second reason is that using FEV6 instead of FVC may underestimate the airflow limitation 
because some patients may need longer than six seconds to achieve FVC (Kaufmann et al., 
2009). The third reason is that we did not use bronchodilators before testing the patients with 
spirometry. The current guidelines for Asthma and COPD recommend the use of bronchodilators 
when performing spirometry (GINA, 2014 & GOLD, 2014). The use of bronchodilators 
decreases the FEV1/FVC ratio, especially in patients with asthma. In the current study, we did 
not use bronchodilators because the aim of our study is to screen the patients and not diagnose 
them. Adding the use of bronchodilators to the screening process could affect the feasibility and 
convenience of our screening method. Further research is necessary to elaborate on the factors 
that affect cut-off values.  
The NPV best reflects the purpose that the PiKo-6 spirometry can have in community 
pharmacy settings: to preselect candidates for full diagnostic spirometry in order to avoid 
unnecessary testing. In our study, the NPV of the pre-BD pRatio (88%) was slightly different 
from the NPVs reported by Bemt et al. and Frith et al. who reported NPV values of 94.4% and 
91%, respectively. Frith et al. (2011) chose a cut-off point corresponding to pre BD pRatio < 
0.75 that offered sensitivity (81%) and specificity (71%). Kaufmann et al. (2009) stated that the 
present analysis of the distribution of pFEV6 and pRatio revealed a sensitivity (40.35%) and 
specificity (100%). Dissimilarities with the previous studies are due to the differences in subject 
recruitment. In addition, the previous studies compared the results of the PiKo-6 against the 
standard spirometry to calculate sensitivity, specificity, PPV, and NPV. There are patients who 
have fixed airway obstruction according the standard spirometry but do not have COPD. Using 
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only the standard spirometry for diagnosis may label patients as COPD when they are obstructed 
for other reasons. These reasons may be available in their medical history. As a result, we 
calculated sensitivity, specificity, PPV, and NPV by comparing the results of the PiKo-6 against 
physician diagnosed COPD (who used a standard spirometer to confirm the COPD diagnosis).   
5.4 The PiKo-6 use in community pharmacy settings 
In a recent study by Solidoro et al., customers of 500 pharmacies in Italy were recruited 
to find probability of obstruction and restriction (Solidoro et al., 2013). Trained pharmacists used 
the PiKo-6 spirometer, without using a bronchodilator, to test the subjects and collected 
information about gender, age, height, weight, smoking status, pharmacology. Pharmacists 
included customers aged between 10-86 years. The aim of the study was to assess the role of 
pharmacists in screening for obstructive and restrictive lung diseases.  
Pharmacists obtained the highest value of three pRatio measures. Customers were 
considered probably obstructed if the pRatio was <70% and probably restricted in the pFEV6 was 
< 75% of the FVC predicted according to the anthropometric data (Solidoro et al., 2013). 
Solidoro et al., stated that patients suspected of suffering from an obstructive lung disease and 
show an obstruction when tested by the PiKo-6 spirometer should be referred to a specialist to 
confirm their diagnosis (Solidoro et al., 2013). The investigators concluded that the PiKo-6 is a 
valid screening tool for the detection of possible airway obstruction and restriction in a pharmacy 
setting. Solidoro et al. stated that this approach could reduce the costs on the health care system, 





5.5 Strengths and limitations of the current study 
The PiKo-6 spirometry and standard laboratory spirometry were completed by different 
professionals and therefore, the effect of possible learning effect of previous blows was 
minimised. The median of the time difference between PiKo-6 spirometry and standard 
laboratory spirometry was 35 days (interquartile range: 18 – 77). Data on these subjects were 
used for analysis as the effect of this time gap was considered negligible.  
Subjects were prescribed medications for their OADs. As shown, there were several 
differential diagnoses for their medication prescription, of which the largest part (n = 26/63) 
consisted of ‘Asthma’. ‘COPD’ was another recurring indications for medication prescription (n 
= 19). For GPs it is difficult to differentiate between COPD and asthma, given the significant 
overlap in the clinical presentation of these two conditions. The current study may have been 
biased as the recruited subjects were seeking medications for their breathing problems. The 
prevalence of disease is likely higher than the general population which will improve the 
screening utility.  
Withholding of medication was not enforced because the study aimed to approximate the 
‘real-life’ use of the device for opportunistic-targeted screening. As there was no instruction to 
withhold bronchodilator medication, there is a possibility that the study included subjects with 
well-controlled or inactive asthma, subjects with only minor obstructive changes, or subjects 
with asthma who had taken their bronchodilator before their visit.  
There were some statistically significant differences observed in the baseline 
characteristic between the patients who were recruited from the pharmacy records, community 
patients, and patients who volunteered to perform the PiKo-6 spirometry in community 
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pharmacies. These differences could be attributed to the limited sample size. The sample 
characteristics of the patients who attended the community pharmacies and patients in the 
community who were recruited via the pharmacy records are summarized in Appendix 3.    
In this study we assessed the repeatability of the PiKo-6 device. To our knowledge, there 
are no published reports about the repeatability of this particular device. However, our results  
cannot be generalized to other portable spirometers other than the PiKo-6. Another limitation is 
that we did not have information about the quality and reproducibility of the full laboratory 
spirometry measurements. The PFT laboratory saved only the best FEV1 and FVC values in their 
database, thus we relied on the professional judgement of the lung function staff at the primary 
care diagnostic centre. Only half of the pharmacists that were invited to participate in the study 
agreed to participate in the study. This could introduce a limitation of this study as the pharmacy 
participation rate may not allow for the generalizability of the results. 
5.6 Implications for future research and practice 
The algorithm used in this study suggested that, if the patient is suspected of having an 
airway obstruction from the use of the PiKo-6 spirometry in a community pharmacy, the 
pharmacist will notify the patient’s primary care physician for a complete diagnostic workup. 
Although we recruited patients who are seeking medication for their breathing problems, we 
recommend that future studies could focus on patients presenting with risk factors for airway 
diseases and patients who were not tested with spirometry in the past.  
To our knowledge, this was the first validation study to determine the validity of the 
portable PiKo-6 spirometer in a community pharmacy setting. Given the findings from this 
study, we suggest that, the PiKo-6 spirometry could provide pharmacists with a simple method to 
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preselect patients for further diagnostic workup by their GPs, if it was lacking. The simplicity of 
the PiKo-6 spirometry may be able to fit into the tight work schedule of the pharmacists.  
The PiKo-6 spirometry may facilitate early, targeted pharmaceutical interventions aimed 
at reducing the burden of COPD. The effectiveness of such pharmaceutical interventions needs 
to be evaluated as well, as robust evidence on this issue is currently lacking. Further studies are 
recommended to assess the role of the pharmacists in screening and management of patients with 
OADs. In addition, future studies should consider the cost utility analysis and the effects on the 
patient’s quality of life, hospital admissions, and early discharge.  
Confirmative diagnostic spirometry remains essential among patients suspected of having 
an airway disease (high pRatio ≤ 0.80). A false-positive by the PiKo-6 spirometry test could be 
the result of reversible airflow obstruction (i.e., asthma). The PiKo-6 spirometry cannot rule out 
asthma and should not be used to preselect patients at risk for asthma. We recommend future 
screening studies to either focus on asthma or COPD, as both diseases have different diagnostic 
procedure. Screening for COPD in community pharmacies does not require reversibility testing. 
Thus, it is more practical to screen for COPD than asthma in a community pharmacy setting. 
5.7 Conclusion 
Although pre-BD PiKo-6 device significantly underestimated pFEV1, on average, the 
pRatio correlates well with standard spirometry FEV1/FVC data. The PiKo-6 could be used as a 
simple screening tool to preselect subjects for a full diagnostic spirometry. However, the PiKo-6 
should not replace standard diagnostic spirometry. It is proposed that portable spirometry 
combined with questionnaires may play a role in screening patients with SOB symptoms in 
community pharmacies that may benefit from early physician diagnosis and appropriate 
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management. Close cooperation between pharmacists, general practitioners, and pulmonary 
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Sample characteristics of the patients who volunteered to perform the PiKo-6 in 
community pharmacies compared with patients in the community who were 












Age, yrs: Mean (SD)  53.9 (15.3) 45.22 (17.4) 0.001* 
Sex, Male: n(%) 33 (52.4) 66 (37.7) 0.043* 
Average BMI: Mean (SD) 31.92 (7.4) 29.93 (7.6) 0.077 
Prior History of Asthma: n(%) 38 (60.3) 74.8 (61.7) 0.447 
Prior History of  COPD: n(%) 11 (17.5) 17 (9.7) 0.102 
Caucasian: n(%) 47 (74.6) 160 (91.4) 0.001* 
Smoking: n(%) 12 (19.0) 39 (22.3) 0.591 
Allergies: n(%)                    43 (68.3) 151 (86.3) 0.002* 
Diabetes Type 2: n(%) 7 (11.1) 9 (5.1) 0.105 
CAD: n(%) 5 (7.9) 12 (6.9) 0.775 
Hypertension: n(%)             24 (38.1) 36 (20.6) 0.006* 
High Cholesterol: n(%) 14 (22.2) 19 (10.9) 0.025* 
Prior Heart Failure: n(%) 1 (1.6) 4 (2.3) 0.740 
Current Depression: n(%) 16 (25.4) 60 (34.3) 0.194 
MRC Dyspnea Scale: Mean (SD) 2.25 (1.12) 2.03 (0.93) 0.131 
Prior PFT: n(%) 31 (49.2) 55 (31.4) 0.012* 
Prior Chest x-ray: n(%) 30 (47.6) 102(58.3) 0.144 
Prior Echo: n(%) 8 (12.7) 27 (15.4) 0.600 
Prior ECG: n(%) 27 (42.9) 86 (49.1) 0.392 
Prior Methacholine: n(%) 0 (0) 2 (1.1) 0.394 
Previously given a diagnosis for SOB 
symptoms: n(%) 
                34 (54.0) 135(77.1) 0.001* 
Systolic (mean) 125.92 123.64 0.450 
Diastolic(mean) 76.79 77.61 0.651 
*Significant Level P < 0.05. 
SD: Standard Deviation, Yrs: years;  COPD: Chronic Obstructive Pulmonary Disease; CAD: 
Coronary Artery Disease; MRC: Medical Research Council ; PFT: Pulmonary Function Test; 
Echo: Electrocardiogram; ECG: Echocardioraphy.    
 
